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IN'mODUCTION 
A nead has existed in pharmacology, ph~siology and medicine for 
drugs which block or reduce the effects mediated over the sympatho-
adrenal nervous s~stem. While many such drugs (of. 39) have been de-
scribed in the past, they have failed to meet the requirements which 
would make them particularly useful. In brief, these compounds, among 
them yohimbine, ergot, Prisooline, and dioxanes, haTe lacked completeness 
of action, are too toxic, and, worst of all, their activity has not been 
limited predomi~y to blockade of the sympatho-adrenal system (39). 
These drugs, therefore, are spoken of as lacking specificity of action. 
Specificity is a term that has long been used in pharmacology to 
characterize the ac~ion of a given drug, or class of drugs, but inasmuch 
as the intimate mechanism of drug action is unknown, this characteristic 
is difficult to define in all embracing terms. For example, specificity 
has been defined to imply that a drug may exert a definite type of effect 
to a degree which is in sharp contrast to other less prominent effects, 
which may eTen be produced by unrelated processes (30). This was applied 
originally to antihistaminics, but, with respect to general pharmacology, 
this definition does not apply equally well to all drugs. 
This is eTident when one considers the fact that the muscular paraly-
sis produced by proper doses of curare is its most prominent effect, yet 
iA terms of mechanism of action, the paralysis is the result of a specific 
antagonism of acetylcholine at a selected site, the neuromuscular junc-
tion. Myanesin likewise produces paralysis but does so by interrupting 
transmission of impulses through interneuronal pathways within the central 
1 
nervous system (20). Thus, in terms of end effect, Myanesin and curare 
are closely related; yet in terms of mechanism of action, they are dis-
similar, for Myanesin blockade of interneurone is apparently unrelated to 
an anti-acetylcholine action (4). 
Specificity, therefore, cannot be defined in terms of prominent effects 
(symptoms), but must be left to describe properties of drugs more closely 
related to their mechanism of action. Hence, the term has been applied to 
drugs which owe their effects to blockade of acetylcholine, histamine, 
and epinephrine at all or selected sites, and likewise it has been applied 
to those which interfere with cholinesterase, or other enzymes, and so 
forth.* 
Applied to adrenergic blocking drugs, specificity of action implies 
that guch drugs would be capable of blocking or reducing the effects of 
endogenous or exogenous epinephrine or sympathins exclusively. Hence, 
from present knowledge the activity of these compounds would of necessity 
be limited to the tisgues innervated by the sympatho-adrenal division of 
the autonomic nervous system. Specificity, unfortunately, does not appear 
to be absolute within any single drug, and it is therefore necessary to 
seek drugs which are relatively specific in action. 
Because of the nature of the projected uses of adrenergic blocking 
drugs, the study of new agents should involve the relative ability to 
antagonize epinephrine and/or nor-epinephrine, acetylcholine, histamine. 
and other active substances that occur naturally. For example, adrenergic 
*Specificity cannot be adapted to characterize numerous classes of drugs, 
including central nervous system stimulants and depressants, digitalis-
like compounds, interneuronal blocking agents, and a host of others un-
til further study reveals their mode of action. 
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blocking drugs h~e often been employed in the study of the various 
functions of the sympathetic ~erTous system, and the use of a drug that 
blocked or potentiated acetylcholine, as well as epinephrine, would co~ 
plicate i1terpretation of the data. The relatiTa ability to antagonize 
effects of nor-epinephrine, histamine, epinephrine and acetylcholine can 
be studied by the !A vitro use of an appropriate test object. These 
methods, however, do not yield information concerning activities that do 
not depend upon antagonism of any of the above .... named, naturally occurring 
substances. In addition, an iA vitro study on a given test object does 
not insure that the relative specificity obserTed with a given drug 
carries over in an identical manner to the intact animal, or even to 
another !A vitro test object. 
In spite of these difficulties, studies on !A vitro test objects 
are still of Talue since they can be easily ~uantitated and are 
relatiTely free of interpretative complications. In addition, they 
offer some basis for selection of drugs to be used in the clinic and in 
research as experimental tools. As pointed out above, however, it would 
be dangerous to rely on a single type of study, and experiments desigaed 
to elucidate the range of activity in the intact organism are of value 
in the final selection of the most specific compound. 
The following sections of this report deal with 1) the pharmacology 
of some newly-developed adrenergic blocking drugs, namely the aryl-B-
haloalkylamines, which show promise of meeting the long-desired need in 
this field; 2) an experimental method of studying specificity of actio• 
as applied to certain of the most promising members of these amines; and 
iii 
3) experiments in intact animals to study, in some measure 1 the site of 
action of the most specific compounds. 
iT 
PH.ARMACOLOGY OF .ARYL-.HALOALKYI4.MINES 
A REVIEW 
The adrenergic blocking properties of the aryl-haloalkylamines were 
first described in 1945 by Nickerson (40, 41), although aryl-derivatives 
had been known since 19.32 (39). Of the series of derivatives reported, 
N, N-(2-chloroethyl)wdibenzylamine (Dibenamine) was the most effective, 
and a considerable amount of li tera.ture has accumulated confirming and 
extending Nickerson's observations (cf. 39). Subsequently, other workers 
have reported on derivatives other than the dibenzyl substituted ethyl-
amine, all of which show adrenergic blocking properties comparable to 
Dibenamine (14, 18, 21, 25, 31-33, 59). 
The introduction of compounds derived from aryl substitution of 
B--chloroethylamine into pharmacology is important from two standpoints: 
firstly, evidence exists suggesting that certain of these drugs exhibit 
other than adrenergic blocking action. Certain members are cholinergic 
in action ,( 14, 21); others show strong a.n.tihistaminic potentialities 
(29, 311 32), and others exhibit atropine-like properties under appro-
priate conditions (see below). These diverse potentialities are in 
addition to prominent adrenergic blocking activity, and a search for 
members exhibiting a single potentiality (or predomnently so) may 
yield gratifying results. Secondly, the known biochemical activity 
exhibited by nitrogen mustards has been applied to the aryl-haloalkyl-
amines (43) and has emphasized the need for chemical interpretation of 
drug action as well as steric interpret~tion that has heretofore been 
so popular. 
The pharmacology of adrenergic blockade has been extensively reviewed 
1 
recently by Nickerson (391 42) and a review here would be only repetitious. 
The following discussion is intended to be a brief resume of the pharmaco-
logy of aryl-haloalkylamines 1 with particular reference to their speci-
fic! ty of action. 
Chemistry: The aryl .... haloalkylamine adrenergic blocking drugs are all 
closely related to the nitrogen mustards by virtue of the single B-
haloethyl group, but are conside~ably less toxic (39). The compounds 
usually are slightly soluble in water and exhibit various degrees of 
instability in aqueous solutions. At low pH, stability is greatest, and 
in aL~aline solutions, these compounds are rapidly (several minutes) con-
verted to their respective inactive hydroxy derivative (14, 50). Chemi-
cal reactivity of these agents has been compared to that of the nitrogen 
and sulfur mustards (43) which have been thoroughly studied (50). 
The number of aryl-haloalkylamines which h~e been examined for 
adrenergic blocking properties is relatively large. Nickerson (43, 47) 
has reported on the blocking properties of about two hundred aryl deriva-
tives, and Loew (31-33) has studied an additional one hundred compounds. 
Not all compounds synthesized have proved to be exceptionally active. 
The most interesting and active drugs which hBYe been studied more or 
less extensively are shown in Table I. 
Pharmacology: Structure-activity relationships. Nickerson (43, 47), 
Loew (31-33), Hunt (21), and Uyllot, et al. (25, 59) haye made extensive 
studies of various aryl-haloalkylamines with regard to structure-activity 
relationship. All workers are in general agreement for the basic require-
ments for adrenergic blocking activity among these drugs. They have been 
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TABLE I: Chemical structure of the more common aryl-2-haloalkylamine 
adrenergic blocking drugs. 
Drug and Formula 
QcH2 
"'N-DH2-DH2-Dl Qa< 
N,N-(2-Dhloroethyl)-dibenzylamine 
(Dibenamine) 
fH2-cH3 
~CH2-N-cH2-cH2-Br 
N-(2-Bromoethyl)-N-ethyl-1-naphthalene-
methylamine. (SY-28) 
2-(2-Biphenylyloxy)-2-chloro-triethyl-
amine. (SY-8) 
Dose to reverse 
epinephrine pressor 
response in the dog, 
mgm./kgm.(Reference). 
10-20 (41) 
0.2-1.0(9, 10, 31, 58) 
Ca 5.0 -cat (39) 
3-5 (32) 
3 
TABLE I (continued). 
N-Et~1-N-(2-chloroet~l)-9-fluorenamine 
(SY-21) 
N-Et~1-N-(2-chloroethyl)~enz~dr.y1-
e.m:ine. (SY-2) 
0 
CH2 
I· . CH2-cH3 0 -<J-CH2-c~-~~-c~-c1 
N-Et~1-N-(2-chloroethy1)-(2-D-benzy1)­
phenoxyethylamine 
4 
0.5-1.0 . (11, 25) 
10-20 (9, 33) 
2-5 (18, 19) 
TABLE I (continued) • 
CH3 
~-yH2-cH2-E( 
c1 c~ 
N, N-Dimethy1-2-chloro-2-pheny1ethylamine 
(D:MEA) 
0 
CH2 
r\ YH3 I 
"---"-0-CH2-GH2-N-cH2-GH2-c1 
N-Benzy1-N-(2-chloroet~1)-phenaxyisoprop,y1-
amine (688-A) 
5 
5-10 (14) 
1-5 (47) 
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discussed at length (43), and, briefly, are: 1) only tertiary or quaternary 
amines are active; 2) the drug must include at least one E-haloalkyl 
group capable of forming an active intermediate, the corresponding ethyl-
enimmonium (or vinyl) derivative; 3) an unsaturated ring substituent must 
be attached to the amine, and, according to Nickerson (43), this allows 
stabilization of the active intermediate. In addition, this ring must not 
be out of plane with the haloalkyl group. 
The reaction, typical of all nitrogen and sulfur mustards (50), of 
the E-chloroethyl group to yield the reactiYe intermediate is shown: 
If20 
\ /N - CH2 - CH2 - OH 
Hydroxy derivative 
Ethylenimmonium 
The ethylenimmonium ion is the reactiTe intermediate in this type of 
adrenergic blocking agent (43) and has the property of reacting with many 
inorganic and organic radicals by condensation (50). The ion has been 
studied with regard to attack of a wide variety of compounds and enzymes 
of biological interest (50). 
Since the publications of the above-outlined structural requirements 
for adrenergic blocking activity within the aryl-substituted halogenated 
ethylamines, certain a~ects hare come to light which require special 
comment: 1) It has been claimed recently that quaternary derivatives of 
Dibenamine are inactive in toxic doses of 20 mgm. /kgm., intravenously, in 
the cat (24). The positive results obtained by Nickerson (43) and Nyman, 
7 
et al. (48, 49) were found to be due to faulty preparation of the quaternary 
compound; namely, the product isolated in the preparation was dibenzyl~ 
:B-bromoethylamine rather than the quaternary ammonium salt. 2) the com-
puunds, · 
and 
are ac~ive as adrenergic blocking drugs (3) and differ from the 9-fluorenyl . 
derivative (SY-21, Table I), and Dibenamine only in that the B-chloroethyl 
group has been replaced by methyl sulfate and toluene sulfate radicals. 
In addition, the phenoxyethyl-benzyl-amines need not depend upon a halo-
alkyl substituent in order to produce epinephrine reversal in cats, al-
though the character of the blockade produced by these compounds differed 
qualitatively from the haloalkyl substituted phenoxyethylamines (4?). 
Thus. the above-outlined requirements for adrenergic blocking activity 
are not strictly adhered to in all respects. Nonetheless, the theory set 
forth by Nickerson has led to synthesis of more active drugs (43), and• 
in addition, has led to consideration pertaining to chemical interpreta-
tion of drug action, as well as steric interpretation, which is also 
important in defining activity within these compounds (43, 4?). 
While most of the knowledge concerning the chemical reactivity of 
the B-haloalkyl group has been done in connection with the nitrogen mustards• 
it is considered that the same type of reactions are involved in producing 
adrenergic blockade by the aryl derivatives (43 1 50). The specific bio~ 
chemical points of attack by these drugs, however, are unknown, and their 
elucidati.on must await further study. But it is of interest to note that 
while phosphokinases (hexoki.nase and adenosinetriphosphatase) are sus-
ceptible to nitrogen mustards (50), interference with muscular contractile 
mechanisms does not occur nonspecifically with aryl-deriva tives (39). 
The se facts suggest some qualitative differences between the nitrogen 
mustards with Di benamine-like compounds, and warns against applicat ion of 
the indirect knowledge accumulated from the studies involving the nitrogen 
mustards. 
M.renergic, blocking :propertie,s: The ability to reduce, block, or reTerse 
responses to endogenous and exogenous epinephrine or sympathins appears 
to be qualitatively the same among all members of the aryl-haloalkyl-
amines described to date (39). The effector cells involved in excitatory 
responses of smooth muscle to adrenergic stimulation are particularly 
susceptible to blockade, while those involved in cardiac acceleration 
(in mammals), vasodilatation and other smooth muscle inhibitory mechanisms 
appear to be absolutely refractory (39). 
8 
Epinephrine pressor responses are more easily blocked (i.e. by lower 
doses) than equipressor responses to norepinephrine in the intact cat and 
dog, but not the spinal cat (15). This indicates that this is most likely 
due to lack of significant vasodilating properties of norepinephrine (1, 46). 
Hence, evaluation of adrenergic blocking drugs should involve the ability 
to block norepinephrine rather than epinephrine pressor effects which was 
made the basis of comparison of the extensive series studied by Nickerson 
(43, 47). 
Certain metabolic . activities exhibited by epinephrine and nor-
epinephrine are blocked with these agents: 1) the hyperglycemic effects 
of epinephrine are reduced or abolished by a wide variety of aryl-halo-
alkylamines (26); 2) the accelerating effects of epinephrine and nor-
epinephrine on blood clotting mechanisms have been shown to be blocked by 
adrenergic blocking drugs (61); and 3) the anti-curare effects of epine-
phrine are abolished by previous administration of Dibenamine (34). 
Dibenamine (6o) and the dihydrogenated ergot derivatives (23) are claimed 
not to block or reduce the calorigenic effects of epinephrine. but more 
careful work is required before this question can be settled. Epine-
phrine-induced release of adrenocorticotropic hormone was reported to be 
resistant to blockade by Dibenamine (39). but the more potent 9-fluorenyl 
derivative, (SY-21, Table I) 1 produced partial blockade of this response, 
as judged by a reduced eosinopenia response to epinephrine (53). 
The aryl-haloalkylamine-type adrenergic blocking agents resemble in 
their pharmacologic effects all other adrenergic blocking drugs previously 
described, and the foregoing is a brief description of the pharmacology 
of adrenergic blockade produced by any drug. Nickerson (39) has reviewed 
the pharmacology of other adrenergic blocking agents (ergot, imidazoline 
derivatives, yohimbine, and the dioxanes) and has emphasized their non-
specificity. The aryl-haloalkylamines differ from these in 1) specificity 
of action and 2) duration and mode of action. These will be discussed 
briefly below. 
9 
Specificity £!adrenergic blockade ~ aryl-haloalkylamines: The high 
degree of specificity of action of Dibenamine has largely been inferred 
from lack of evidence to the contrary. The intravenous administration of 
the drug produces no effects that cannot be referred to blockade of the 
adrenergic nervous system. and, in addition, does not alter acetylcholine, 
angiotonin, barium, posterior pituitary-induced responses on blood pressure 
of various species, and responses of a variety of isolated smooth muscle 
preparations, (cf. 39) in d.oses well above those required to block epine-
phrine. Likewise, Dibenamine does not alter the depressor or decelerator 
responses to electrical stimulation of the vagus in the dog (39) or alter 
synaptic transmission through the isolated superior cervical ganglion of 
the cat in amounts that can be considered non-toxic (27). Benzby.dryl.;.. 
derivatives (SY~, Table I) appear to be qualitatively similar with re-
spect ~o specificity of action inasmuch as they are relatively free of 
antihistaminic properties as well as the above (33). 
This relatively high order of specificity is somewhat surprising in 
view of the presence of the highly reactive essential group, B~haloethyl­
amine. Studies involving alkylation of biochemical substances with nitro-
gen mustards reTealed that a wide variety of amino acids, di- and tri-
peptides1 nicotinic acid, pyridoxine, and so forth, as well as certain 
enzymes, including cholinesterase, cholinacetylase, and phosphokinases, 
are attacked (50). It is possible that the presence of the single halo-
alkyl and aryl radicals modify the reactiveness of the ethylenimmonium 
ion and confer some degree of specificity for a particular enzyme or 
other biochemical substrate, as is suggested by the specificity of action 
10 
of Dibenamine and the closely related benzhydryl derivatives. 
The importance of the n~ture of the aryl radical is further brought 
out by the fact that other aryl substitution produces compounds showing 
other kinds of action in addition to adrenergic blocking properties. 
l) Some members of the alpha-naphthyl derivatives (SY-28, Table I) de-
scribed by Loew are exceptionally potent antihi staminics (29a 31, 32). 
In addition the phenoxyethyl substituted agents show appreciable anti-
histaminic activity (44), as d.o the liphenylyloxy-ethyl derivatives (32). 
The E-chloroethyl group is essential to antihistaminic activity, but 
adrenergic blocking action and antihistaminic activity do not parallel 
each other (44). It is most likely that any E-chloroethylamine with 
adrenergic blocking activity will show some degree of histamine blocking 
properties. 2) Anticholinergic properties of some of these drugs has 
ll 
been mentioned• but not studied in detail (44). 2-(2~biphenylyloxy)-2-
chloro-triethylamine (SY-8. Table I) and N-(2ebromoethyl)-N-ethyl-l-
naphthylenemethylamine (SY-28, Table I) appear to possess anticholinergic 
properties as shown by their ability to re.duce acetylcholine-induced spasm 
of the isolated seminal vesicle of the guinea pig1 although this activity 
is far below that of atropine under the same conditions (see below). 
Anticholinergic activity does not parallel antihistaminic or anti-epinephrine 
activities (44). 3) Cholinergic properties h~e been described for 
N, N-dimethyl-2-chloro-2-phenylethylamine (DMEA, Table I) (14) and for 
the fluorenyl derivative (Table I). DMEA appears to be significantly 
more potent in this regard for intravenous doses of as little as 0.5 mgm./ 
kgm. in dogs produced decreases of blood pressure that were abolished by 
atropine (14). SY-21 required 1000 times the epinephrine blocking dose to 
exhibit potentiation of the acetylcholine-induced spasm of isolated smooth 
muscle (see below). Cholinergic properties of these drugs is not surpris-
ing since the nitrogen mustards are relatively potent cholinesterase in-
hibitors (2, 22), and anticholinesterase activity has been described for 
certain of the aryl substituted amines (2). Cholinergic properties were 
absent in the hydroxy derivative of DMEA (14), suggesting that the E-
chloroethyl group is required for this action as well as antihistaminic 
and antiepinephrine properties. 
In mxmmary, aryl-haloalkylamines show a potentially broad spectrum 
of pharmacologic activity. While the E-haloalkylamine group appears to 
be essential for epinephrine blocking action, antihistaminic and cholinergic 
activity, the nature of the aryl substitution has a distinct modifying 
influence, and it is conceivable that in the future aryl-haloalkylamines 
will be uncovered which show predommently only one of the above-named 
activities. The relatively broad spectrum of action of these drugs makes 
it imperative that these activities of a single drug be expressed in 
quantitative terms so that confident use can be made of the drug in the 
clinic and as experimental tools. 
Duration and mode of action: The aryl-haloalkylamine adrenergic blocking 
drugs are characterized by a particularly long duration of action, differ-
ing in this respect from all other drugs possessing adrenergic blocking 
properties (39). Administration of these agents intravenously in effec-
tive doses results in persistent blockade, as judged by the ability to 
block or reverse epinephrine pressor effects for as long as 30-72 hours 
12 
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(17, 62). Dogs given the 9-fluorenyl derivative (SY-21 1 Table I) in oral 
doses of 5 mgm. /kgm. twice daily for two weeks 1 showed. evidence of epinephrine 
reversal for as long as ten days after discontinuance of the drug (13). 
The persistence of action of these drugs is unique among adrenergic 
blocking drugs (39) 1 and, in general, is unparalleled among agents of other 
classes. Dibenamine has been shown to be deposited rapidly, in a matter 
of minutes 1 in fat depots after intravenous administration in dogs (?). 
This has been invoked to explain the long duration of action (?). The 
fact that prior administration of dioxanes shortens the duration of action 
of subsequently injected Dibenamine to an hour or one and one-half hours 
(55) is not in keeping with such an interpretation for it is highly un-
likely that dioxanes in doses of 2-3 mgm.fkgm. would alter the solubility of 
Dibenamine in body fats. The long duration of action of aryl-haloalkyl-
e~ines is more likely related to irreversible destruction or inactivation 
of some substance (or "receptor") upon which epinephrine and sympathin 
act to produce their typical effects. 
Such an interpretation ~s supported by consideratiOns pertaining to 
the mode of action of these drugs. The aryl-haloalkylamines exert a 
competitive-type inhibition early during onset of action (39), or if 
antagonism studies are made with minimally effective doses (10). After 
blockade is once established, however, the action appears to be non-
competitive for the reason that large doses of epinephrine cannot over-
come the blocking effect and that the drugs (apparently) cannot be washed 
off effector cells of isolated smooth muscle preparation (44 1 56). This 
dual mechanism of action appears to apply for histamine antagonism as well 
(39, 44), but when acetylcholine inhibition occurs, it is partially 
reversible (see below). Ergot and derivatives, yohimbine, Priscoline, 
and the dioxanes apparently act solely by competition for the epinephrine 
or sympathin-sensitive receptors (cf. 39) and the blockade produced does 
not persist for as long a period of time. 
Summary: Aryl~~halogenated ethylamines appear to be the most satis-
factory adrenergic blocking agents described to date. In common with 
all other adrenergic blocking drugs, they-possess the ability to block or 
reverse all excitatory influences of epinephrine or adrenergic stimula-
tion on smooth muscle. and certain metabolic effects, but the inhibitory 
influences of epinephrine, as well as the effects of mammalian heart 
muscles are unaltered. 
Aryl, and/or alkyl substitution of one or two ]-chloroethyl groups 
of the nitrogen mustards has led to reduction of toxicity, but the 
potential chemical reactivity of the remaining E-chloroethyl group appears 
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to be unaltered. Nonetheless, the nature of the aryl substitutent has a 
distinct modifying influence in this reactivity since benzhydryl. d_ibenzyl 
and 9-fluorenyl substituents possess predo~ly anti-epinephrine properties; 
alpha-naphthyl. phenoxyethyl, and biphenylyloxyethyl derivatives possess 
antihistaminic and anti~etylcholine activities in addition to adrenergic 
blocking properties. Furthermore. distinct cholinergic properties h~e 
been described for other aryl substituted derivatives. The E-chloroethyl 
group appears to be essential for all of the activities, and apparently 
confers the long duration of action and the completely or partially 
irreversible nature to the blockade produced. The relatively broad spectrum 
of action which these drugs possess makes quantitative specificity studies 
assume even greater importance in order that the most specific compound 
can be used in research and in the clinic with greater reliability. 
15 
ANTAGONISM OF EPINEPHRINE, NOR-EPINEPHRINE, IDSTAMINE AND ACETYLCHOL!1'T]] 
EFFECTS ON THE ISOLAT:ED SEMINAL VESICLE 
OF THE GUINEA PIG :BY .ARYL-HALOALKYLAMINES. 
AN EXPERIMENTAL STUDY. 
Numerous adrenergic blocking drugs (sympatholyties, adrenolyties) 
have been described in the literature since Dale first demonstrated the 
adrenergic blocking properties of ergot and derivatives (12"). SUch com-
pounds have frequently been tried in disease states in which the sympathetic 
nervous system is believed to be involved. They have, in addition, been 
employed widely in physiologic and pharmacologic investigations in an 
attempt to evaluate the role of the sympathetic nervous sys_tem in various 
responses. 
The use of these drugs in the clinic and, particularly, as experi-
mental tools demands that they possess a high order of specificity and 
selectivity of action in diminishing responses mediated over the sympatho-
adrenal nervous system. All adrenergic blocking drugs, prior to the 
description of N, N-(2-chloroethyl)-dibenzylamine (Dibenamine) by Nickerson 
(41) have lacked these requisite properties. SUbsequent investigations 
(14, 18, 21, 25, 31-33, 59) have shown that many aryl-haloalkylamines, of 
which Dibenamine was the first, possess the ability -to produce adrenergic 
blockade. 
While the aryl-haloalkylamines appear to be the most satisfactory 
adrenergic blocking drugs yet described, not all members are equally 
specific or potent in .action. Thus, all aryl•haloalkylamines having 
appreciable epinephrine blocking ability likewise have the ability to 
diminish or block histamine effects to one degree or another (29, 31. 32). 
Indeed, the alpha-naphthylmethyl derivatives of B-chloroethylamine appear 
to antagonize histamine as strongly as epinephrine (31). The scope of ac-
tion is not limited to adrenergic and histamine blocking properties, but 
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extends to the acetylcholine-cholinesterase system. N, N-dimethyl-2-
chloro-2-phenylethylamine (DMEA), for example, possesses definite 
cholinergic properties (14); still other halogenated ethylamine compounds 
diminish acetylcholine responses (see below). 
The degree to which a single compound possesses all of the above 
properties varies; hence, from a fundamental, as well as practical stand-
point, it is important to characterize the relative specificity of the 
agents in quantitative terms. While such studies have been made in con-
nection with drugs of other classes, notably the antispasmodics (63) and 
antihistaminics (8, 51, 54), no such study has been reported with regard 
to the aryl-haloalkylamine blocking agents. With this in mind several of 
the more promising and interesting aryl-haloalkylamines have been chosen, 
and the relative abilities of antagonizing epinephrine, nor-epinephrine, 
histamine, and acetylcholine effects on a single test object have been 
determined. 
~uantitative specificity studies are most easily done by !A vitro 
methods, since conditions can be controlled exactly, and the results ob-
tained are easier to interpret. In vitro methods have been applied to 
antihistaminics (51, 54, 63) and to antispasmodics by several workers. 
Most workers have used the gut of either the guinea pig or rabbit. With 
these test objects the relative ability to antagonize histamine, acetyl-
choline, and barium ions can easily be determined and such studies are of 
definite value. The value of such studies can be increased by use of test 
objects which react in the same manner to all spasmogenic agents studied.· 
With the gut as the test object, epinephrine and nor-epinephrine are 
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excluded since these cause relaxation rather than contraction. The guinea 
pig seminal vesicle, however, is contracted by all of the naturally occur-
ring substances mentioned above and from this alone would appear to be the 
idealtissue for specificity studies. 
The seminal vesicle of the guinea pig has been employed previously 
for potency determination of various dihydrogenated derivatives of ergot 
with respect to epinephrine antagonism (52) and for specificity studies 
of various imidazolines (36), but little information is ~ailable in these 
reports cancer~ the adaptability of the tissue to biological ass~. 
The experiments reported herein deal with a description of the pharmacology 
of the seminal vesicle of the guinea pig and its ad~tability to specificity 
studies as applied to ~ecificity of action of selected aryl-haloalkylamine 
adrenergic blocking drugs. 
Method: The Magnus method of study of isolated tissue was employed. 
Locke's solution with 0.1 per cent dextrose added was used as the bathing 
fluid and kept at 39 ± 0.5° C. by means of a thermostatically-controlled 
water bath. The perfusion fluid was aerated by oxygen, introduced at the 
bottom of the muscle chamber by means of a small polyethylene catheter. 
All solutions of drugs were freshly prepared daily when their stability 
in solution was unknown; otherwise, stock solutions were prepared at 
appropriate intervals. Drugs were added to the 100 cc. muscle chamber 
by means of 1/4 to 1.0 cc. tuberculin syringe; the volume added never 
exceeded 1.0 cc. and ordinarily was 0.5 cc. or less. 
Male guinea pigs weighing 350 to 600 grams were killed by a sharp 
blow on the head, and the entire seminal vesicles were removed at 
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laporatomy. These structures are ordinarily straight, tubular structures 
varying from 4o-80 mm. in length (in the weight group employed). The dis-
tension produced by the seminal fluid varied considerably, and it was 
noticed that, if exceptionally full, the contents prevented maximal con-
tractions. Hence, a small opening into the lumen was u~ally placed close 
to the tied off proximal end. Both vesicles, so prepared, were placed in 
the muscle chamber by ·the usnal technique, and the contractions induced by 
various drugs were magnified 14-18 times by means of a nearly isotonic 
frontal writing lever, modified after Schild (54), and recorded on a 
slowly-moving kymograph. 
The seminal vesicles, under these conditions, were generally quiescent 
and exhibited activity only after the addition of an appropriate drug to 
the snrrounding fluid. Rhythmical, spontaneous contractions sometimes 
occurred, but the magnitude of these was always slight compared to the 
maximal effects of various spasmogenic agents. Two types of studies were 
made: 1) the dose-response relationships to the action of spasmogenic 
(active) drugs were determined, and 2) the antagonism by blocking agents 
of these spasmogenic ~ffects was studied. The exact procedures involved 
in each type of study are given later since the details of each study 
differ somewhat. The general procedure, however, can be given here. 
From the determinations of the dose-response curves of the active 
drugs, a dose was chosen of each spasmogen (epinephrine, nor-epinephrine, 
acetylcholine and histamine) which produced an average of 80-90 per cent 
of the maximal response, as determined on 10-12 separate vesicles. These 
standard doses ware used throughout the course of the antagonism investi-
gations. These quantities were introduced into the muscle chamber, allowed 
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to remain in contact with the tissue for one minute, and washed out of the 
chamber by displacement and dilution; fresh, preheated Locke 1 s solution 
was introduced at the bottom, and the displaced fluid was drawn off at 
the top of the muscle chamber by suction. The fresh locke's solution was _ 
allowed to flow through the muscle chamber for one minute. The diameter 
of the inlet and outlet tubes was such as to allow 400-500 cc. of fluid 
to pass through the chamber during this interval. A five-minute rest 
period ensued, at the end of which the cycle was repeated either with the 
same active drug or others used alternately. 
These responses recorded in millimeters served as control responses 
to be compared with responses obtained in the presence of the antagonist. 
The details of the exact procedure (see below) with respect to the antag-
onism studies varied with the nature of the d.rugt but, in all cases, the 
antagonist was added four minutes prior to the active drug; hence, the 
antagonist remained in contact with the tissue a total of five minut.es (four 
minutes alone plus one minute during the test contraction of active drug). 
The active drug and antagonist were washed out as before, and if responses 
to the active drug were nearly the same as before addition of the antagonist, 
more than one dose of antagonist was studied on the same strip. 
The dose~response relationship of the various spasmogens was deter-
mined in order that equally effective doses could be used for the compara-
tive specificity studies. The general procedure was given in a previous 
section. The effects of graded doses of various spasmogens were deter-
mined on separate vesicles with no attempt being made to randomize the order 
of doses. The doses of each spasmogen, beginning with the threshold dose, 
were increased by doubling the amount of the previous dose until no further 
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increase in the recorded response was obtained. The last two responses 
obtained were ~eraged and considered as the maximum effect, and the 
effects of all previous doses were compared with these in terms of par-
centage of maximal action. 
The spasmogens examined in detail included epinephrine hydrochloride*, 
containing no more than 0.1 per cent nor-epinephrine, histamine diphosphate*, 
acety~choline chloride, and nor-epinephrine bitartrate.** All doses were 
calculated in terms of the bases and expressed as micrograms per 100 cc. 
The details of the exact procedures involved with regard to the 
antagonism studies were as follows: 
1. Antagonism of the effects of epinephrine and nor-epinephrine by 
aryl-haloalkylamines: After obtaining two control responses each to 
standard doses of epinephrine and nor-epinephrine (200 meg. of the base/ 
100 cc.), given alternately, a given amount of antagonist was added, 
and either epinephrine or nor-epinephrine was added to the bath, and 
the reaction recorded. Inasmuch as the order of addition of spasmogen 
was alternated with each new strip, one-half of the experiments were 
made with epinephrine and the antagonist present in the bath simu.l-
taneously, and the other half with nor-epinephrine. Thus, in one-half 
of the experiments the effect of antagonist on a spasmogen was tested 
after the antagonist had been washed out of the bath. However, the 
activity of aryl-haloalkylamines has been shown to be irreversible 
with up to four washings under these conditions (56); consequently, 
the data were pooled. 
*Generously supplied by Parke Davis and Company. 
**Generously supplied by Sterling-Winthrop, Inc. 
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In a few preliminary experiments, acetylcholine and histamine 
were likewise tested simultaneously with epinephrine and nor-
epinephrine; generally, however, epinephrine or nor-epinephrine were 
tested in the presence of the antagonist, or after one washing. The 
concentrations of antagonists in these preliminary experiments were 
below those required to block or reduce histamine or acetylcholine 
spasm. 
The responses to epinephrine and nor-epinephrine obtained in the 
presence of antagonist, or after one washing, were compared to the 
average of two of their respective controls, as per cent reduction of 
the control value. The data were treated statistically as described 
below. 
__ 2. Antagonism of histamine and acetylcholine spasm by aryl-haloalkylamines: 
The antagonism studies involving histamine and acetylcholine were done 
in parallel in the same manner as carried out with epinephrine and 
nor-epinephrine. The standard test doses were 200 mcg./100 cc. The 
concentration of antagonists required to reduce acetylcholine spasm 
was, however, far greater (5-150 times) than those required to 
diminish or block histamine effects. Hence, to test the effects against 
acetylcholine either a second dose of antagonist was given after the 
effect of the first on histamine spasm had been noted, or as usually was 
done, fresh strips were employed and acetylcholine antagonism tested 
aJ.one. 
The responses obtained to histamine in the presence of the antag-
onist or after the antagonist had been removed by one washing were 
22 
compared to the control values obtained just prior to the addition of 
the antagonist. The results were expressed as per cent reduction of 
the control and treated statistically in the manner to be described. 
The data involved in the anti-acetylcholine studies were handled in 
the same manner, with the exception that test responses to acetylcho-
line were always obtained in the presence of the antagonists since the 
anti-acetylcholine activity was partially reversible by washing. 
In experiments of this nature, it is best to test a reference 
standard in conjunction with a test drug on the same strip. This was 
obviated by the fact that the effects of the aryl-haloalkylamines were 
completely or partially irreversible by washing. This necessitated 
the use of a fresh seminal vesicle for each dose of antagonist; a 
total of 10-23 experiments were made for each of 3-4 doses of each 
antagonist. 
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3. Blockade of epinephrine, histamine, and acetylcholine spasm by atropine 
and pyranisamine:* Experiments with atropine sulfate* and pyranis-
amine*, a relatively specific anti-acetylcholine drug and antihistaminic, 
respectively, were made for comparative purposes. 
The effects of these agents could be reversed by washing, ani more 
than one dose of antagonist against a given spasmogen was tested on 
the same strip. Three to four doses of antagonist were used against 
the same spasmogen on a given strip; studies with the other active 
drugs were made on separate strips. The order of addition of the in-
dividual doses of antagonist to a given strip was randomized in a 
*Generously supplied by Merck and Company. 
total of 12-16 separate experiments involving each spasmogen; this 
served to spread equally, throughout the 3-4 doses used• variance due 
to changes in sensitivity. 
Again, test responses were compared \vi th control responses ob-
tained immediately before addition of the antagonist, and, as before. 
were expressed in terms of per cent reduction of the control value. 
Statistical Evaluation Procedures: The data obtained in the manner just 
described are of the measurement, or graded response type {6). Statisti-
cal procedures which h~e been devised for analysis of this type of data 
are extremely laborious to carry out (3?). Certain of the features of 
the antagonism of the various spasmogens, and also the nature of the con-
traction to the active drugs are such as to warrant converting these data 
to the quantal, or all-or-none type and applying the more rapid methods 
of analysis to such data (3?). The rationale for applying quantal analysis 
to essentially measurement data has been pointed out by Miller (38) 1 and 
will be alluded to in the following sections. 
The measurement data described above were converted to all-or-none 
data by designating ~hat a given trial with an antagonistic drug was a 
negative trial if the per cent reduction (as compared to control response 
to the spasmogen) was less than 50 per cent. A given triBl was called 
positive if the per cent reduction was 50 per cent or greater. Thus, small 
doses of antagonist yielded relatively few positive responses, and increas-
ing the dose resulted in an increasing proportion of positive trials. 
~antal data of this nature are easily handled, from a statistical 
viewpoint, by graphic methods of analysis. The method applied here is 
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that described by Litchfield and Wilcoxon (28) v1hich enables one to cal-
culate linearity of the given regression lines; parallelism between two 
or more regression lines; ED50 values of each, including the 95 per cent 
confidence limits; and relative potency between drugs. ED50 doses when 
calculated by quantal analysis indicates the quantity of any drug that 
will produce 50 per cent or greater inhibition of the spasm induced with 
the active drug, in 50 per cent of the trials. 
Results: 
1. Contraction characteristics of the guinea pig seminal vesicle: The 
isolated seminal vesicles of the guinea pig exhibited little or no 
sponte~eous activity. Any spontaneous activity that did occur did 
not interfere with quantitative me~surements of contractions in-
duced by appropriate active drugs. 
Contractions induced by active drugs commenced after a latent 
period of 10-15 seconds during which time the drug was dispersed 
throughout the muscle chamber. In all cases the maximum effect 
exerted by histamine. epinephrine, acetylcholine and nor-epinephrine 
reached a maximum within a one-minute exposure interval. A:n:y activity 
due to the presence of an active drug was immediately interrupted 
after one minute by washing, and the tissue relaxed to its original 
state of quiesence within a period of 2-3 minutes. 
Reactions of tissue to the various aforementioned spasmogens 
differed somewhat in the characteristics of the responses produced 
by each. Acetylcholine produced a more sudden contraction, which 
reached peak effects in a shorter period of time than any other agent 
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studied. Furthermore, contractions induced with histamine, epinephrine, 
and nor-epinephrine were characterized by considerable rhythmical 
activity, superimposed upon the elevated tonus level. On the other 
hand, this was usually absent in the response to acetylcholine. Such 
rhythmicity detracts from accurate determination of the true response, 
end was one of the reasons for converting the data to the quantal type 
(see below). Typical records of contractions induced with the various 
active drugs are included in Figure 1. 
Other agents were also found to be effective in causing contrac-
tion of the isolated seminal vesicle. These include barium ions, 
potassium ions, pilocarpine, nicotine and ephedrine• The characteris-
tics of the contractions induced by these were similar to those de-
scribed for epinephrine with the exception of the barium salts which 
produced weak contraction of slow onset and prolonged interval for 
peak effect (3-4 minutes, even in doses of 10-20 mgm./100 cc., that is, 
1:10,000 to 1:5,000. 
The effective doses of pilocarpine, ephedrine and nicotine ap-
peared to be in the same range as for epinephrine and nor-epinephrine 
(200 to 400 mcg./100 cc.) in the few experiments that were done. These 
drugs were not studied in detail, but it is of interest to note the 
wide range of sensitivity that the seminal vesicle possesses. Because 
of the fact that all active drugs studied produced contractions, it 
should be possible to study the antagonistic effects of blocking agents 
on a b~oad spectrum of relative effectiveness against many spasmogens. 
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2. The dose-response relationship of epinephrine, nor-epinephrine, hista-
mine, and acetylcholine on the isolated seminal vesicle of the guinea pig: 
-------=· ==---
Fl.gure 1: Typical kymograms of the contraction of the isolated seminal vesicle of 
the guinea pig induced b,y epinephrine (E), nor-epinephrine (N), 
acetylcholine (A) and histamine (H) • The dose of each was 200 micrograms 
(of the base) per 100 cc. Notice the rhythmical activity of the peak of 
each contraction, except that produced by acetylcholine. 
Table 11: The effect of graded doses of various spasmogens on the 
isolated seminal vesicle of the guinea pig. 
Spasmogen 
Epinephrine 
hydrochloride 
Nor-epinephrine 
bitartrate 
Histamine 
diphosphate 
Acetylcholine 
chloride 
Doses: meg. of 
base/100 cc. 
No. 
Exp. 
13 
9 
12 
15. 
Per cent of ~~ximal Effect* ± Stand Deviation 
14.6 25.8 43.5 68.6 81.8 93.1 97.4102.9 
±7.4 ±9.6 ±10.3 ±10.9 ±9.2 ±7.2 ±4.9 ±4.2 
14.5 21.4 35.9 59.9 79.7 91.7 99.0 100.0 
±14.0 ±16.0 ±18.8 ±15.5 ±11.8 
-±5.9 ±1.8 ±2.1 
13.9 32.7 49.7 71.5 88.6 91.9 100.0 98.7 
±6.1 ±9.1 ±11.2 ±9.7 ±6.9 ±7.3 ±5.2 ±6.5 
26.7 39.1 51.7 74.7 83.3 91.0 97.6 102.5 
±10.5 ±14.9 ±13.6 ±17.6 ±14.5 ±15.0 ±5.9 ±6.7 
10 20 40 100 200 400 1000 2000 
*The maximal effect was taken as the average of the responses, in mm., 
obtained to the two highest doses. 
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The effects of graded doses of the various active drUgs were studied 
in some detail. 
The pattern of the response appeared not to vary with the dose 
except that, particularly with histamine and acetylcholine, the doses 
near the maximal range tended to produce less rhythmical activity at 
the peak of the response than smaller doses. Standard doses of 
active drugs used in the antagonism studies were therefore near maxi-
mal. 
Standard test doses of epinephrineT nor-epinephrine, histamine, 
and acetylcholine were chosen from the near maximal range, as depicted 
in Table II and Figures 2 and 3. The doses were 200 meg. of the base/ 
100 cc. for each and produced 80-90 per cent of the maximal effect. 
The absolute re~onse (in millimeters) that these amounts produced 
varied considerably from animal to animal, as well as with the 
different drugs (Table III). 
It is noted in Table III that acetylcholine, particularly, and 
histamine produced responses of greater magnitude than either epine-
phrine or nor-epinephrine. This is reflected in average values, 
appearing in Table III, but it was also much more apparent when these 
agents were tested alternately on the same strip with the same 
magnification of the contractions. It was mentioned that each of 
these doses was chosen from the same region of its respective dose re-
sponse curves, when such curves were considered in terms of per cent 
of maximal effect. Hence the doses in these terms are nearly equally 
effective, but nonetheless produce contractions of differing magnitude. 
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Table III: Magnitude of responses of the isolated seminal vesicle of 
the guinea pig to, standard doses of different spasmogens. 
Spasmogen 
Epinephrine 
hydrochloride 
Nor-epinephrine 
bitartrate 
Histamine 
diphosphate 
Acetylcholine 
chloride 
Dose 
meg. of 
base/lOOcc. 
200 
200 
200 
200 
No. of 
Responses 
269 
226 
212 
212 
Responses 
mm ± s* 
Jl.6 ± lJ 
27.0 ± 11 
41.8 ± 18 
6].5 ± 22 
*Values are the average of the responses obtained on separate vesicles 
used in the antagonism studies with the various aryl-haloalkylamines. 
The standard deviations were approximated by the method outlined in 
Snedecorts Statistical Methods, the 10\va State College Press, 4th Ed., 
1946, :page 99. 
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Figure 2: Dose-response curves of graded doses of epinephrine and nor-epinephrine 
on the isolated seminal vesicle of the guinea pig. Note typical hyper-
bolic curves result when the data from Table II are plotted against 
dose (lower scale) while a sigmoid curve forms from the same data 
plotted on a logrithmic scale (upper scale). 
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Figure 3: Dose-response curves of graded doses of acetylcholine and histamine on 
the isolated seminal vesicle of the guinea pig. Note that the curves 
are similar in all respects as those in Figure 2. 
This suggests that more muscle fibers respond to acetylcholine than 
to the other drugs tested. 
Such factors as ease and rate of diffusion to effector cells, 
relative rate of destruction and inactivation are probably involved 
but would b.e . difficult to evaluateo It is believed that these 
factors alone could not account for such a result. If this were so, 
it should be possible to increase the concentration of any active 
drug to the point which produces effects equal to that of any other 
drug. This was not borne out by these experiments since maximal 
effects of acetylcholine were always greater in terms of millimeter 
response than any others. 
The results could be explained on the basis of selective permea-
bility which was independent of concentration of active drug. It 
would be of interest to determine the effects of perfusion of the 
tissue with Locke's solution containing hyaluronidase to determine 
whether this agent would equalize the difference between the spasmogens. 
It is to be noticed that the approximated standard deviations of 
the mean responses of the spasmogens listed in Table III are relatively 
large. These large variations were due to differences in responses 
of individual pigs; a given strip gave relatively reproducible con-
tractions upon repeated exposure to a given spasmogen. In addition, 
two vesicles of the same pig yielded responses which were less vari-
able than between pigs. This is to be expected for it has been 
reported that variations in responses of different segments of the 
same guinea pig ileum are remarkably small (54). The large variation 
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in sensitivity to spasmogenic agents carried over to the blockade of 
their effects by antagonistic drugs. but part of this was reduced by 
calculating the inhibited responses due to antagonist in per cent of 
the control value (see Table IV for the magnitude of variation.) 
Control experiments have shown that repeated contractions do not 
vary significantly over a 3-hour period when contractions were 
elicited in ?-minute cycles by the various spasmogens (56). Exactly 
reproducible contractions were not obtained, and in the antagonism 
studied, a closer approximation to the true value was approached by 
using the average of the two preceding control responses obtained 
just prior to addition of the antagonist. Inasmuch as most of the 
data obtained in the antagonism studies were converted to all-or-none 
responses with the limit for a positive trial being set at greater than 
50 per cent reduction in the expected response, slight variations did 
not play a significant role. 
3. Antagonism of the effects of various spasmogens by certain blocking 
drugs: It has been shown in the preceding sections that the reaction 
of the isolated seminal vesicles of the guinea pig to active drugs 
lend themselves to study of the relative specificity of antagonistic 
drugs in blocking the effects of these. The antagonism of the effects 
of the spasmogens was of the nature of reduction in the height of the 
expected response, as compared to controls obtained in the absence of 
the antagonist; hence, such data are of the measurement or graded 
response type. As mentioned previously, these data were converted to 
the all-or-none type by signifying any trial with an antagonistic 
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drug--a negative one if the response to the spasmogen was 50 per cent 
or more of the control value. Conversely, a positive trial produced 
50 per cent or greater inhibition under the same conditions. 
The result of converting measurement data to all-or-none is 
presented in Table IV. It can be seen that the mean per cent reduction 
increased proportionately with the dose. The incidence of positive 
trials likewise increased with the dose, as is to be expected. It 
is of interest, however, that mean per cent reductions need only to 
be in the neighborhood of 60-70 per cent of control value for 80-100 
per cent of positive trials to result. 
It is to be noted that considerable variation occurs around the 
mean per cent reduction values observed in Table IV. This is particu-
larly true with regard to epinephrine and nor-epinephrine antagonism. 
The large variation was due mainly to variation between guinea pigs; 
the variation between strips of the same pig appeared to be consider-
ably less. 
In spite of this rather large variation, the dose-response rela-
tionships depicted in Table IV, expressed as regression coefficients, 
all differed significantly from zero. Furthermore, ED50 values cal-
culated from regression lines (5) based on these data had relatively 
narrow 95 per cent confidence limits (see Table VIII). 
While it is possible to compare regression lines based on 
measurement data for linearity, parallelism, and relative potency, 
it is much more laborious to ca:rry out than corresponding quantal 
analysis. The data presented below have been analyzed statistically 
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Table IV: Inhibition of drug-induced spasm of the isolated seminal 
vesicle of the guinea pig by certain drugs. 
SPASMOGEN: EPINEPHRINE - 200 meg. of the base/100 cc. 
Antagonist Dose 
mcg/lOOcc 
Ne N-(2-Chloroethyl~ 
dibenzylamine. HCl 
(Dibenamine) 
1.25 
2.50 
5.00 
N-Ethy1-N-(2-ch1oro- 0.313 
ethyl)-benzhydrylamine 0.625 
HC1~ , (SY-2) 1.250 
2-(2-Eipheny1y1oxy)-
2•-ch1oro-triethy1-
amine. HCl (SY-8) 
N-Ethy1-N-(2-ch1oro-
ethy1)-9-f1uorenamina 
HCl (SY-21) 
N-(2-Bromoethy1)-N-
ethyl-l-naphthalene-
methylamine. HEr 
(SY-28) 
Atropine Sulfate 
1.00 
2.00 
4.00 
8.00 
0.125 
0.250 
0.500 
1.000 
0.50 
1.00 
2.00 
375 
750 
1500 
3000 
Percent Reduction 
± s* 
30.4 ± 15.1 
46.3 ± 15.2 
67.1 ± 13.5 
19.1 ± 13.1 
44.9 ± 15.1 
78.2 ± 14.9 
. 18.6 ± 12.5 
)2.1 ± 13.1 
57.2 ± 19.1 
79.2 ± 12.5 
16.4 ± 16.1 
31.6 ± 21.4 
44.2 ± 19.8 
71.0 ± 13.4 
23.1 ± 17.9 
46.7 ± 23.8 
59.1 ± 19.4 
19.7 ± 7.2 
33.6 ± 8.9 
51.5 ± 8.4 
66.7 ± 10.2 
No 
Exp. 
16 
15 
10 
13 
23 
17 
8 
15 
17 
13 
13 
19 
20 
14 
8 
14 
14 
16 
16 
16 
16 
Per cent of 
Positive Trialst 
o.o 
46.7 
90.0 
0.0 
30.4 
94.1 
o.o 
13·3 
82.) 
100.0 
o.o 
15.8 
40.0 
92.8 
o.o 
28.5 
78.5 
o.o 
6.9 
62.5 
87.5 
35 
3"6 
Table IV (continued). 
SFASMOGEN: NOR-EPINEPHRINE - 200 meg. of the base/100 cc. 
Antagonist Dose Percent Reduction No Per cent of 
mcg/lOOcc ± s* Exp. Positive Tria1st 
N, N-(2-Ch1oroethy1)- o. 62.5 26.6 ± 16.2 8 12 • .5 
dibenzy1amine. HC1 1.2.50 41.8 ± 12.4 14 21.4 
(Dibenamine) 2.,500 .54.1 ± 13.3 1.5 .53.4 
,5.000 74.6 ± 12.1 10 100.0 
N-Ethy1~N-(2-ch1oro- 0.313 24.6 ± 1.5 • .5 17 o.o 
ethy~benzhydry1- 0.62.5 49.4 ± 21.1 23 .52.1 
amine. HC1 (SY-2) 1.2.50 77 • .5 ± 19.4 13 94.1 
2-(2-Biphenyl~xy+ 1.00 21 • .5 ± 13 • .5 8 12 • .5 
21-ch1oro-trietb¥1- 2.00 42.3 ± 20.1 1.5 33·3 
amine. HC1 (SY-8) 4.00 67.9 ± 17.8 16 81.3 
8.00 8).8 ± 10.6 13 100.0 
N-Ethy1-N-(2-ch1oro- 0.12.5 18 • .5 ± 13.1 12 8.3 
cthy1)-9-fluorenamine. 0.2.50 3.5.1 ± 22 • .5 18 16.7 
HC1 (SY-21) 0.,500 .52.0"" ± 19.4 19 .58.0 
1.000 76.4 , ± 13.1 14 100.0 
Table IV (continued). 
SPASMOGEN: HISTAMINE - 200 meg. of the base/100 cc. 
Antagonist Dose Percent Reduction No Per cent of 
mcg/lOOcc ± s* Exp~ Positive Trialst 
N, N-(2-Chloroethyl)- 20 37.0 ± 7.9 12 8.3 
dibenzylamine. HCl 27 44.2 ± 8.7 12 16.7 
(Dibenamine) 40 48.6 ± 17.3 11 72.7 
60 66.8 ± 12.9 10 100.0 
N-Ethy1-N-(2-chloro- 27 48.5 ± 11.3 12 58.3 
ethyl)-benzhydryl- 40 49.7 ± 15.1 12 58.3 
amine. HCl (SY-2) 60 58.5 ± 14.0 12 66.7 
80 65.6 ± 11.7 12 91.6 
2-(2-Biphenylyloxy)- 4.0 40.5 ± 7.1 13 15.4 
2r-chloro-triethyl- 6.0 48.2 ± 11.5 12 33·3 
amine. HCl (SY-8) 8.0 54.0 ± 15.6 12 75.0 
N-Ethyl-N"(2-chloro- 6.7 35.8 ± 12.9 8 12.5 
ethyl)-9-fluorenamine. 10.0 47.5 ± 11.1 15 46.6 
HCl (SY-21) 15.0 59.1 ± 11.7 12 83.3 
N-(2-Bromoethyl)-N- 0.50 35.6 ± 6.7 12 16.7 
ethyl-1-naphthalene- 0.75 50.6 ± 10.4 12 50.0 
methylamine. HBr 1.00 63.7 ± 9. 0 12 100.0 
(SY-28) 
Atropine Sulfate 150 27.4 ± 8.1 12 o.o 
300 41.1 ± 10.6 16 25.0 
600 60.0 ± 11.1 15 73-3 
1200 76.8 ± 8.4 16 100.0 
Pyranisamine 0.025 29.5 ± 6.7 6 
-0.050 48.3 ± 6.3 8 
0.100 68.4 ± 7.5 6 
Table IV (continued). 
SPASMOGEN: ACETYLCHOLINE - 200 meg. of the base/100 cc. 
Antagonist Dose Percent Reduction No Per cent of 
mcg/lOOcc ± s* Exp. Positive Trialst 
2-(2-Eiphenylyloxy)~ 12.5 J2.1 ± 5.6 12 o.o 
2•-chloro-triethyl- 25~0 49.0 ± 11.6 14 57.1 
amine. HCl (SY-8) 50.0 69.0 ± 7.2 8 100.0 
N-(2-Eromoethyl)-N- 50 2J.J ± 5--1 11 o.o 
ethyl-1-naphthalene- 75 47.6 ± 7.1 10 30.0 
methylamine. H:Br 100 48.1 ± 6.1 12 50.0 ' 
(SY-28) 150 69.8 ± 12.2 10 100.0 
Atrop ine Sulfate 0.17 Jl.2 ± 10.7 10 10.0 
0.25 44.9 ± 7.4 12 JJ.J 
0.37 57.7 ± 15.8 12 66.7 
0.50 63.0 ± 8.1 10 90.0 
*Per cent reduction of the response to the active drug in the presence of 
the antagonist as compared to the control responses obtained in the ab-
sence of the antagonist. 
tA positive trial is a response to active drug obtained in presence of 
antagonists which differs from corresponding control by a 50 per cent 
or more reduction. 
TABLE V: Antagonisrn of drug-induced spasm of the isolated seminal vesicle of the ~uinea pi g by various 
agents. 
Antagonist 
mcg./lOOcc. 
N, N-(2-Chloroethy~ 
Epinephrine 
EDsot 
SPASiiiOGEN~<-
Nor-epinephrine Histamine Acetylcholine 
- ---- -------- - ---
dibenzylamine. HC l 2.60 (1.82 to 3.72) 2.06 (l.L.6 to 2. 90) 33.9 
(Dibenamine) 
+ (28.7 to 4o.o) 2ooo+ 
N-Ethyl-N-(2- chloro- t 
ethyl) -benzhydT'IJl- 0.755 ( . 62 to .92) 0.61 (0.49 to • 76) 33 .5 (24 .6 to L6.6) 1ooot 
amine . HC l (SY-2) 
2-(2-Biphenylyloxy)-
21-chloro-triethyl- 3.03 ( 2. L 2 to 3. 7 9) 2. 42 (1. 82 to 3.24) 6 . 26 (5.08 to 7.68) 24.0 (19. 5 to 29.6) 
amine. HJ1 (SY- 8) 
N-Ethyl-N-(2-ch1oro-
ethyl-9-f1uoren- 0 .52 (.37 to 0.70) 0.41 (0.29 to .53) 10.4 ( 8 • 3 9 to 12 • 9) -;¥ 
amine . HCl (SY-21) 
TABLE V (continued) 
Anta gonist Epinephrine 
__ __;:.___, 
mcg./lOOcc . ED5ot 
N-( 2-Bromoethyl) - N-
etl~l-1-naphthalene- 1.37 (1.09 to 1.71) 
methylamine . HBr 
(SY-28) 
Atropine Sulfate 1330 (980 to 1810) 
Pyranisamine "" 12, 000 to 24,ooo+ 
SPASMOGEN-l:-
Nor- epinephrine Histamine Acetylcholine 
------------------------~--------
ED5o ED5o 
(0.60 to . 84) 93.0 (77 . 8 to llh) 
435 (351 to 539) 0 . 30 (0 . 22 to . 41) 
t 
0.053§ (0.050 to 0.55 ) 1 2, 000 to 24.,000+ 
-1:-The standard dose of each spasmogen was 200 meg. of the base/100 cc. 
l That quantity of antagonist which produces 50 per cent or greater reduction in response to spasmogen, 
compared to control s , in 50 per cent of the trials . The figures in parenthesis are the 95 per cent 
~confidence lirnits . 
+These quantities produced slight spasm themselves, and are therefore only approximations. 
//SY-21 potentiated acetylcholine-induced contractions . 
§Value forecast from graded response dose- effect line. See page '53 
Comparison can be made between drugs with respect to potency, using 
one of them as a standard of comparison. This has been done in Table VI 
using the compound marked with an asterisk as the standard. The potency 
ratio (P. R.) was derived by dividing the larger ED50 by the smaller; 
hence, from Table VI, SY-21 is 1.4 times as potent as SY-2; 2.5 times as 
potent as SY-28, and so forth, in antagonizing epinephrine-induced spasm 
of the seminal vesicle. 
Of more interest than potency comparison is the relative ability of 
a single compound to antagonize the various active drugs. This has been 
accomplished in Table VII. The potency ratio has been derived as indicated 
at the head of each vertical column. The ED5o in the denominator of this 
ratio is the reference value; for example, ED50HistfED50Epi ratio for 
SY-21 equals 20.0. This indicates the antagonism is twenty times more 
specific against epinephrine spasm than histamine ,spasm, inasmuch as 
twenty times the amount of drug blocking epinephrine was needed to block 
histamine to the same degree. 
While SY-21 was the most potent antagonist of epinephrine examined, 
it is not as specific as SY-2, which is some forty-four times more 
specific against epinephrine than histamine. Dibenamine, on the basis 
of these experiments, appears to possess the same order of specificity as 
SY-21 as regards epinephrine and histamine antagonism (Table VII). SY-8, 
on the other hand, exhibited little discrimination between any of the 
active drugs employed. One member of the series, the alpha-naphthylmethyl 
derivative of 2-chloroetbylamine (SY-28) was nearly twice as active against 
histamine as epinephrine (Table VII); hence, on this basis one would be 
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TABLE VI: Comparative potency of antagonists of drug---induced spasm of the isolated seminal vesicle of the 
guinea pig. 
Spasmogen: Spasmogen: Spasmogen: Spasmogen: 
Epinephrine No r-epine- Histamine Acetylcholine 
Antagonist An tag. phrine An tag. iAn tag. 
mc.'!:/lOOcc P. R. f mcf!.! lOOcc P. R. mc.'!:/lOOcc P. R. lmc.e:/lOOcc P. R. 
N-Ethyl-N-(2-chloro-
ethyl)-9-fluoren- 1.0 SY-21* 1.0 SY-28* 1.0 SY-8* 1.0 
amine. HCl (SY-21)* 
N-Ethyl-N-(2-chloro-
ethyl)-benzhydryl- 1.44 SY-2 IJ..49 SY-8 8.6 SY-28 ~-72 
amine. HCl (SY-2) (o. 99-2.10) (1.04-2.24) (6.78-11.4) (2. 84-4. 85) 
N-(2-Bromoethy1)-N-
ethy1-l-naphtha1ene- 2.64 SY-28 
-
SY-21 IJ..4.6 
methylamine. H:Br (1. 82-J. 86) (11.2-18.9) 
(SY-28) 
N, N-(2-Ch1oroethy1)-
dibenzylamine. HC1 5.0 Diben. ~.OJ SY-2 ~7.2 
(Dibenamine) (J.l2-8. 0) (3.21-7. 84) (JJ. 8-68. 0) 
TABLE VI (continued) 
Spasmogen: Spasmogen: Spasmogen: Spasmogen: 
[Epinephrine No r-epine- Histamine Acetylcholine 
Antagonist .An tag. Ehrine An tag. .An tag. 
mce/lOOcc P. R.i mce/lOOcc P. R. mce/lOOcc P. R. mce/lOOcc P. R. 
2-(2-Eiphenylyloxy)-
2•-chloro-triethyl- ~.83 SY-8 5.90 Diben. 47.9 
amine. HCl (SY-8) (3. 96-8. 6) (). 98-8. 75) (38.6-59.4) 
Atropine 5~lfate ~560 Atropine 
-
Atropine 613 Atropine .00125 ·-
(1650-3840) (466-803) (.00095-.00164) 
*All comparisons made with drug marked with the asterisk as the standard. 
tpotency ratio (P.R.) obtained by developing the ED50 standard into the ED50 of the drug to be compared. 
Hence, all values are referred back to the standard, and potency is expressed as the number of multiple s 
the standard is as potent as the compared compound. (see text). The values in parentheses are 95 per 
cent confidence limits of the potency ratio. 
TABLE VII: Relative specificity of antagonists of drug-induced spasm of the isolated seminal vesicle of 
the guinea pig. 
Antagonist ED.50Norepi/ED50Epi* ED5oHist/ED5o~~i ED5QA.ch/ED50Epi ED)OAch/ED50Hist 
N, N-(2-Chloroethyl)~ o. ?9 13.1 Ca.??O Ca.60 
dibenzylamine. HCl .(0.48-1.30) (8.9-19.2) 
(Dibenamine) 
N-Ethyl-N-(2-chloro- 0.81 44.7 Ca.1330 Ca.l65 
ethyl)~benzhydrylamine (. 61-1.08) (31. ~61+.2) 
HCl. (SY-2) 
2-(2-Biphenylyloxy)- 0.80 2.06 7.9 3. 84 
2'-chloro-triethyl~ (.57-1.12) (l-.53-2. ?9) (5.9-10.5) (2. 87-5. 09) 
amine. HCl (SY-8) 
N-Ethyl-N-(2~chloro- 0.?9 20.0 
ethyl)-9-fluorenamine. (.51-1.20) (13. 7-29.2) 
HCl (SY-21) 
N-(2-Bromoethyl)-N- 0.52 67.9 131 
ethyl-1-naphthalene- ( .39-. 69) (51.5-89. 6) (104-165) 
methylamine. HEr 
(SY-28) 
*Values are those derived as indicated from ED5o 1s in Table V (see text). 
TABLE VII (continued) 
Antagonist 
Atropine Sulfate 
Pyranisamine 
J.06 
(2.22-'-~.44) 
25,000-50,000 
4440 
(2880-6810) 
Ca.l.O 
ED50HistfED50Ach 
1450 
(1000-2100) 
*Values are those derived as indicated f rom ED50 1s in Table V (see .text). 
25,ooo-5o,ooo 
tempted to classify this drug as an antihistamic. Its activity against 
histamine, however, did not approach the activity shown by pyranisamine 
under the same conditions (Table V). The relative specificity of any of 
the drugs examined can be seen by reference to Figure 4. 
It is of interest to note that the antagonism of epinephrine and nor-
epinephrine closely approached each other with each of the aryl-halos~kyl­
amines studied (Table VII). This ratio of the ED50Norepi to the EDSOEpi 
was constant for each drug, and closely approximated 0.80. On the basis 
of the data in Table VII, this ratio was not significantly different, 
inasmuch as the 95 per cent confidence limits overlap. Nonetheless, En50 
values (see Table VIII) calculated from ~urement data regression lines 
showed that this difference in activity was significantly different in 
two of the four drugs (SY-1 and SY-8). In the other two cases, significant 
differences would be obtained by increasing the number of experiments. 
Q.ua.litatively, all of the aryl-haloalkylamines studied showed the 
same kind of inhibitory activity against epinephrine, nor-epinephrine or 
histamine effects. The activity, however, differed with respect to acetyl-
choline spasm in that certain drugs (SY-8 and SY-28, Table V) inhibited 
this response, others (SY-2 and SY-1) had little or no effect, and SY-21 
potentiated the spasm produced by actylcholine. It is to be noted in 
Table VII that EDSOAch of SY-28 was some 68 times the ED50Epi; hence, 
SY-28 was some 68 times more specific against epinephrine than acetyl-
choline. SY-8, on the other hand, was little more discriminating against 
epinephrine than acetylcholine; the ED50Aoh ~ ' ED50EP1 ratio was only 8. 
As seen in Table V, ED50Ach estimations for SY-2 and SY-1 are only 
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Figure 4: Graphical representation of the data in Table VII. The height of each 
vertical column represents the quantity of antagonist required to block 
the indicated spasmogen compared to the blocking concentrations of 
epinephrine • 1.0 (adrenergic blocking agents); acetylcholine • 1.0 
(atropine); histamine= 1.0 (Neo-antergan or pyranisamine). 
rough approximations. The values listed were doses which caused some 
spasm themselves, and yet hardly influenced superimposed acetylcholine 
spasms. SY-21, in doses of 500-1000 mcg./100 co., consistently produced 
potentiation of the effects of acetylcholine in spite of the fact that 
these quantities of SY-21 also caused slight rises in resting tonus of 
the seminal vesicles. 
It was mentioned !I" eviously that epinephrine, nor-epinephrine and 
histamine antagonism by these compounds was completely irreversible under 
the conditions employed (56) • . In view of this, it is of definite interest 
that the acet,ylcholine antagonism shown by SY-28 and SY-8 was ]artially 
reversible by one washing. 
Similar experiments were conducted with atropine sulfate and pyranis-
amine for comparative purposes. The data in Table VII reveal that atro-
pine is some 1400 times more specific against acetylcholine than histamine, 
and 4000 times as compared with epinephrine. Pyanisamine exhibited even 
greater specificity versus histamine, as compared with acetylcholine and 
epinephrine; in each case, 25-50,000 (or greater) times the quantity of 
the antagonist was needed to inhibit acetylcholine and epinephrine-induced 
spasm than that required to inhibit histamine spasm to an equal degree. 
This comparison is an approximation, since quantities of ~isamine that 
were required to partially inhibit adetylcholine and epinephrine spasm were 
in themselves spasmogenic. The extreme specificity of pyranisamine, with 
respect to discrimination between histamine and acet,ylcholine has been 
determined by Schild on the guinea pig ileum (54) • He found that 40 ,000 
times as much pyranisamine was required to inhibit acetylcholine as that 
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which was required to inhibit histamine under the same conditions. 
Discussion: The aryl-haloalkylamine adrenergic blocking drugs are the most 
promising in terms of both specificity and potency of action of those that 
have been described. The relative potency and specificity of certain of 
these drugs has been determined by their ability to antagonize drug-induced 
spasm of the isolated seminal vesicle of the guinea pig. 
The adrenergic blocking properties of the compounds used in this in-
vestigation have been studied previously by other vTorkers (31-33, 41, 58). 
With respect to antagonism of epinephrine, the relative potency of these 
agents agree closely with the results of other investigators. In general, 
SY-1, 2 and 8 have been assigned the same order of potency in this respect, 
while SY-21 and 28 appear to be the most potent antagonists of epine-
phrine among various aryl-haloalkylamines (33, 58). The relative ability 
of these agents to block and reverse the pressor response to epinephrine 
is indicated by the range of doses listed in Table I, as reported by other 
investigators. 
It can be seen from these data that 10-20 mg.m./kgm. of Dibenamine 
(SY-1) and SY-2 are required to produce epinephrine reversal; SY-8 is of 
the same order of potency that has been reported for other biphenylyloxy 
derivatives (32). The most active compounds are SY-21 and SY-28; as 
little as 0.25 to 1.0 mgm./kgm. i.v. is capable of causing epinephrine 
reversal in the dog. 
The relative order of potency with respect to epinephrine antagonism 
reported in this paper, agrees closely with that in Table I with the 
exception that SY-2 was nearly as effective as SY-21, and significantly 
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more potent than SY-28 (Table V), The reason for this is not apparent, 
but such factors as solubility of the drugs in solution and the relative 
rate at which they are converted to the inactive hydroxy derivatives (50) 
must be involved, but difficult to evaluate. Furthermore, the time re-
quired for onset of maximal activity has been shown to be important with 
regard to causing epinephrine reversal in cats (39) and may be involved in 
these !R vitro experiments. Recently, Chen~~. (11) reported that 
SY-2 was as effective as SY-21 in antagonizing the local vascular effects 
of epinephrine. SY-28 was somewhat less effective than either, and the 
results of their experiments are in close agreement with these reported 
here. 
It has been pointed out by Nickerson (44) that any aryl-haloalkjlamine 
exhibiting adrenergic blocking properties likewise is capable of blocking 
various responses to histamine. This general PTOperty has been confirmed 
by the results reported here. The antagonism of histamine by any member 
bears no constant relation, however, to the antagonism of epinephrine; 
this is shown by the fact that ED50Hiat:EDSOEpi ratios vary from 0.5 
to 40 (Table VII). This is in contrast to the relation between nor-
epinephrine and epinephrine antagonism (Table VII), which is nearly 0.8 
for each drug (see below). This indicates that anti-epinephrine potency 
did not parallel anti-histaminic potency within the limited number of 
the aryl-haloalkylamines studied. Likewise, antihistaminic potency did 
not parallel anti-acetylcholine effects within any of the drugs. These 
facts have also been described by Nickerson (44) on a larger series of 
aryl-haloalkylamines, and they do not lend support to the concept that 
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histamine and epinephri~e, and histamine and acetylcholine act upon the 
same or closely related receptors (29). While, perhaps, no fundamental 
significance can be attache& to this general property of aryl-haloalkylamines, 
it is of interest to note that this dual antagonism of epinephrine and 
histamine by a single molecule is not limited to the isolated seminal 
vesicle, but extends to tissues (e.g. vascular system of the dog) which 
react in opposite directions when stimulated by histamine or epinephrine 
(Jl, 32). 
Experiments designed to elucidate the mechanism of action of these 
drugs would be of major importance and interest, particularly with respect 
to the mechanism involved in the antagonism of epinephrine and histamine 
by a single compound. Such experiments have been reported by Chen ~ ai· (10) 
with respect to the ability of ergotami~e to antagonize the vascular 
effects of epinephrine and histamine in the dog. The mechanism of action 
suggested by Chen's data was that of competitive inhibition with reference 
to epinephrine, but a non-specific, unrelated antagonism to histamine. 
Chen, likewise reported that SY-28 exhibited competitive inhibition of 
epinephrine receptors on the vascular system of the dog, but did not ex-
tend this to histamine. 
Previous mention was made of the fact that ED.50Norepi: ED50 ratio .. Epi 
was constant throughout the drugs examined. This result is not surpris-
ing since the two active drugs are very closely related chemically and 
pharmacologically and probably act upon the same receptors. The signifi-
canoe of this ratio is that less antagonist is required to inhibit nor-
epinephrine spasm than epinephrine spasm. Such data suggest that the 
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quantities of spasmogens used were not equally active,* or that the molecu-
lar quantities were not identical. The latter is of necessity true, since 
200 meg. of the base of each were used and the molecular weights are not 
identical. Nonetheless, on a molecular basis, less epinephrine was added 
than nor-epinephrine; hence, it is difficult to explain the preferential 
activity of the aryl-haloalkylamines against nor-epinephrine on this 
basis, especially if the antagonism were of the competitive type. 
In any case the relative activity against epinephrine and nor-
epinephrine is nearly the same, and the greater ease with which adrenergic 
blocking drugs inhibit epinephrine pressor responses as compared with nor-
epinephrine pressor responses (15) can only be explained on the basis that 
epinephrine produces considerably more vasodilatation than nor-epinephrine, 
as has been concluded by Ahlquist (1) and recently by Nickerson (45). 
In spite of the fact that the aryl-haloalkylamines are very closely 
related chemically, only two ( SY-28 and SY-8, Table V) of the five drugs 
produced measurable inhibition of acetylcholine spasm, while SY-21 produced 
I 
potentiation of the acetylcholine response. This unexpected potentiation 
m~ be related to an anti-cholinesterase activity that has been reported for 
some of these halogenated ethylamines (2). However, the fact that SY-28 
which has been shown to inhibit cholinesterase in vitro (2) did not potentiate 
acetylcholine in amounts (500 meg.) well above the median inhibiting dose 
of 93 mcg./100 oc. does not support that hypothesis. Other members of 
this series of compounds--mEA (Table I) has been shown to be strongly 
*Limited dose-response data of the two active drugs indicates that 200 meg./ 
100 co. of either produce equal effects in terms of per cent of maximal 
action (see Table II). 
---·· ····-·· ::-.: 
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cholinergic. The reasons why some of these closely related agents ahould 
block and other potentiate acetylcholine effects are not known. 
Throughout the present report emphasis has been placed upon the fact 
that the results were computed from data originally of the measurement 
type converted to all-or-none, or quanta! data. ED50 , 8 listed in Table V 
were calculated by the usual graphic techniques applied to such data and 
were defined as the quantity of drug which produced 50 per cent or 
greater inhibition of active drug spasm in 50 per cent of the trials. By 
necessity of this definition, the ED50 values calculated from measurement 
dose-effect regression lines, from which the corresponding quanta! data 
were derived, must be identical with those from the probit-log dose 
regression lines. 
This feature is born out by the comparison of the ED5o•s calculated 
from measurement log dose-effect lines and log dose-probit regression 
lines listed in Table VIII. It is seen that confidence limits calculated 
from measurement data are somewhat narrower than from the corresponding 
quanta! data. This is always true of graded response assays (16), and 
the conversion of the original measurement data is a wasteful process 
from a statistical viewpoint. 
This conversion, while wasteful, is nonetheless advantageous since 
the statistical treatment of the data is much easier, particularly when 
the studies are being made on a large scale (routine) basis. 
The precision of the estimates based on graded responses assays was 
of the nature of 10-20 per cent. Precision of this order is ordinarily 
satisfactory for most purposes, but in this case was achieved only at the 
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TABLE VIII: Comparison of ED5o's calculated from measurement-dose effect 
and frow probit-dose effect (quantal) regression n_nes. 
-
Epinephrine Nor-Epinephrine 
Anta gonist 
mcg/100 cc. Measure Quantal Measure Quantal ED so~:- ED5ot ED 5o ED so 
N, N-( 2-Ghloroethyl)- 2.70 2.60 1 . 87 2.06 
dibenzyl amine . HCl ( 2. 25-3 . 25) (1. 82-3.7) (1.57-2.21) (l.L~6-2. 90) 
(Dibenamine) 
N- Ethyl-H-(2-chloro- 0.66 
-755 0.62 0.61 
ethyl) -benzhydryl- ( . 60- . 73) (.62-.92) (.54-. 71) ( . 49- . 76) 
amine . HC l (SY-2) 
2-( 2-Biphenylyloxy)- 3 -33 3.03 2.41 2. 42 
2' -chloro-triethyl- (2 . 91-3.81) (2.42-3 .79) (2.01-2. 88) (1.82-3.24) 
amine . HC l (SY-8) 
H-(2-Bromoethyl)-N- 1.30 1.37 
ethyl-1-naph~halene- ! ( -97-l. 70) (1.09-l. 71) -- --
methyl amine. HBr 
(SY-28) 
N-Ethyl-:J- ( 2-chloro- 0.52 0.52 . 0.43 0 .41 
ethyl) -9-fluoren- (0 . 43-. 63) (.37--70) (0.36- .52) (0.29-.53) 
amine . HCl (SY-21) 
Atropine Sulfate 1435 1330 
-- --(1303-157 8) (980-1810) 
Pyranisamine 
-- - -- --
~:.Calculated from measurement dose-effect regression lines after the method 
of Bliss (5). 
t calculated as described in text. The values in parenthesis are the 95 
per cent confidence limits of the estimate. 
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TABL~ VIII (continued) 
Histamine Acetylcholine 
Antagonist 
---y-· 
mcg/100 cc. \'lea sure Quantal Measure Quantal ED 5o{:· ED5o+ ED 5o ED 5o 
, N-(2-Chloroethyl)- 34 .1 33-9 -- -
di benzylamine . HCl (29.4-39.6) ( 2 8 • 7 -40 • 0) 
(Dibena.mine ) 
N-Ethyl-N-(2-chloro- 40.7 33.5 -- --
ethyl)-benzhydryl- (29.2-56.9) (24.6-45 . 6) 
amine. HCl (SY-2) 
.. 
-
2-( 2-Biphe:nylyloxy)- 5 .70 6.26 25.6 2L1.0 
21 -chloro-triethyl- ( L1 • ~.? -7 .13 ) (5.08-7 .68) (22.8-28. 8) (19.5-29.6) 
amine. EC l (SY-8) 
-
I'J-( 2- Bromoethyl) -N- o . 72 o. 71 93.5 93.0 
ethyl-1-r-..aphthalene- ( . 66- . 78) (. 60- . BL.) (87.9-99 .5) (77 . 0-11L;) 
methylamine. IIBr 
(SY-28) 
-
N-Ethyl-l'J-(2-chloro- 10 . 9 10.L1 
ethyl)-9-fluoren- (9.51-12.7) ( 8 ·39-12. 9) 
-- -
amine . HC l (SY-21) 
Atropine Sulfate 402 435 0.30 0. 30 
(361-446) (351-539) ( .27-.3L.) (0.22-.hl) 
Pyranisarr.ine 0·.053 
- -- -(0.050....056) 
{~alcu1ated from measurement dose-effect regression lines after the method 
of Bliss (5). 
+calculated as described in text. The values in parenthesis are the 95 
per cent confidence limits 9f the estimate. 
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expense of rather large number of experiments, since the variation between 
vesicles was relatively large (see Table IV). 
In spite of the rather large variation between animals with respect 
to the antagonism studies, it is felt that the guinea pig seminal vesicle 
makes the useful test object for the stu~ of drug antagonism. In order 
that the number of experiments be reduced to a minimum for a satisfactory 
assay, w~s of reducing this apparent inherent variability between pigs 
should be sought. It is possible, for example, that use of guinea pigs 
whose weight varied as little as possible would reduce this variation. 
Furthermore, the effect of estrogens and/or androgens on drug responsive-
ness of the vesicle should be investigated for their effect on the varia-
tion observed between pigs. 
Summary: The relative ability of various aryl-2-haloalkylamine adrenergic 
blocking drugs to block the spasmogenic effects of equi-effective doses 
of epinephrine,nor-epinephrine, histamine, and acetylcholine has been 
studied on the isolated guinea pig seminal vesicle. The results have been 
interpreted to indicate the relative potency of the antagonists with 
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respect to antagonism of a given spasmogen, and, also, the relative specificity 
a single antagonist exhibits in antagonizing the various spasmogens. 
All aryl-haloalkylamines studied were found to block the effects of 
epinephrine, nor-epinephrine, and histamine on the seminal vesicle. The 
effect of the blocking agents on the acetylcholine-induced spasm was in-
constant; N-Ethyl-N-(2-chloroethyl)-benzhydrylamine.HCl (SY-2) and N-
(2-chloroetbyl)-dibenzylamine.HCl (Dibenamine) had no effect in non-
spasmogenic amounts; N-ethyl-N-(2-bromoethyl)-1-naphthalene-methylamine. 
HBr (SY-28) and 2-(2-biphenylyloxy)-2*-chlorotrietbylamine.HCl (SY-8) 
blocked, albeit in doses considerably above those required of atropine 
sulfate; and N-ethyl-N-(2-chloroethyl)-9-fluorenamine.HCl (SY-21) 
potentiated acetylcholine-induced spasm. 
N-Ethyl-N-(2-chloroetbyl)-9-fluorenamine (sY-21) was five times as 
potent as Dibenamine in antagonizing epinephrine, although N-ethyl-ll-
(2-chloroetbyl)-benzhydrylamine (SY-2) was more discriminating in this 
regard since 44 times the quantity of drug was required to block histamine 
to the same degree as epinephrine. In this respect SY-21 and Dibenamine 
were 20 and 13 times as discriminating, respectively. 
No parallelism existed among these drugs between the relative order 
of potency with respect to antagonism of epinephrine, histamine, or acetyl-
choline, while such a relationship was found to exist between epinephrine 
and nor-epinephrine. 
The specificity demonstrated with atropine and P,yranisamine agree 
with those reported by Schild, who employed the guinea pig ileum. The 
use of the seminal vesicle, however, has the added advantage in that a 
broader spectrum of drug antagonism can be studied on a single test 
object. 
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EFFECT OF N-ETHYL-N-(2-CHLOROETHYL)-9-FLUORENAMINE.HCL AND 
N-NfHYL-N-(2-CHLOROETHYL)-BENZHYDRYLAMINE.HCL ON PRESSOR RESPONSES 
TO EPINEPHRINE, NICOTINE, AND ADRENERGIC NERVOUS REFLEXES 
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Since the disclosure by Nickerson,~~. (41) that N, N-(2-chloroethyl)-
dibenzylamine (Dibenamine) is a specific adrenergic blocking agent, 
efforts have been made to develop more potent compounds that possessed 
the same, or higher degree, of specificity. A number of more potent com-
pounds have been devel0ped, but at the same time these have exhibited a 
lesser degree of specificity (31, 32). One of these, N-(2-bromoethyl)-
N-ethyl-1-naphthalenemethylamine BBr (SY-28) appears to be one of the 
most potent antagonists of epinephrine among the halogenated etbylamine 
derivatives, yet at the time possesses antihistaminic activity of a 
high order (29, 31). 
Potency and specificity studies carried out on the isolated seminal 
vesicle of the guinea pig have revealed that N-ethyl-N-(2-chloroethyl)-
9-fluorenamine.HCl (SY-21) and N-ethyl-N-(2-chloroetbyl)-benzhydrylamine. 
HCl (SY-2) are sufficiently more potent and specific than Dibenamine to 
warrant further characterization as regards their selectivity of action 
(site of action) as adrenergic blocking drugs. 
Method: A method of study was chosen in which the ability to block the 
effects of injected epinephrine as well as the ability to block the effects 
of sympathetic stimulation could be determined. For this purpose adrenergic 
reflex pressor responses to carotid occlusion and to anoxia were employed. 
In addition, adrenergic activity, manifested as a rise in blood pressure, 
was induced by ganglionic stimulation with small doses of nicotine. 
Mongrel dogs of either sex were lightly anesthetized with pento-
b~bital sodium (25 mgm./kgm., intraperitoneally) and prepared for record-
ing arterial blood pressure from the femoral artery. Certain of the 
experiments were performed in unilaterally (right) vagotomized dogs 
(see Table IX) • 
In testing the effects of adrenergic blocking drugs on sympathetic 
reactivity, the following procedure was employed: 1) epinephrine 
hydrochloride was injected intravenously in a dose of 1 mcg./kgm.; 
2) the carotid arteries were occluded belO\oT the bifurcation for 1 
minute; J) hypoxia was induced by rebreathing nitrogen gas over soda 
lime for 1.5 to 2 minutes, depending upon the magnitude of the response; 
and 4) nicotine was injected intravenously in a dose of 25 mcg.jkgm. 
After repeating each of the above procedures twice, SY-21 in a dose of 
1.0 mgm.jkgm. or SY-2 in a dose of 20 mgm.jkgm. was administered intra-
venously over a period of 5 minutes. The above procedures were then 
carried out again beginning at 10 and 35 minutes after administration of 
the blocking agents, and the responses compared with those obtained prior 
t .o treatment. The pressor responses to the various procedures obtained 
before and after treatment with the adrenergic blocking drugs were analyzed 
statistically by conventional paired data analysis (5?). 
The blocking agents studied are bitter, white crystalline compounds 
which deteriorate in solution on standing or heating, and were, therefore, 
freshly prepared before use. Solution was effected in acidified normal 
saline, containing 10 per cent ethyl alcohol. 
Control experiments in untreated animals have shown that pressor 
responses to epinephrine, nicotine, carotid occlusion, and nitrogen in-
halation remain essentially unaltered for J-4 hour period of experimenta-
tion (58). 
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Results: A. Effects of the blocking agents on the ~essor response to 
epinephrine: The data in Table IX indicate that both blocking agents 
markedly altered the pressor response to epinephrine. The degree of 
reversal after SY-21 was greater than that following SY-2. This is 
suggested by the absolute values~ as well as by the fact the biphasic 
responses (partial reversal) were less frequent following SY-21 and SY-2. 
B. Effect on adrenergic reflex and nicotine pressor responses: The com-
pound SY-21 appeared to be more effective in causing reversal of the 
nicotine and anoxic pressor responses than did SY-2, in spite of the fact 
that the dose of SY-21 was only l/20 of that of SY-2. This is reflected 
by the data in Table IX which show that mean responses following SY-21 
are completely reversed, while those following SY-2 are only incompletely 
blocked. Here again the frequency of biphasic responses were less after 
SY-21 than after SY-2. 
While a differential in activity existed between SY-21 and SY-2 
as regards ability to block and reverse epinephrine and the pressor 
responses to nicotine and anoxia, which depend, in part, upon the re-
lease of endogenous epinephrine; no such difference is apparent with 
respect to blockade of the response to carotid occlusion (Table IX). 
The fact that no adrenergic blocking drug has been reported to cause 
reversal of this response suggests that epinephrine is not released 
reflexly during the response. Partial or complete blockade of this 
pressor reflex would therefore be an adequate measure of the ability 
of a drug to block direct sympathetic nervous 'influences upon the 
vascular system 1 providing the influence of lowered arterial pressure 
was considered, as suggested by Maison,~~. (J5). 
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Table IX: Alterations of pressor responses to injected epinephrine, nicotine, and adrenergic reflexes. 
Epinephrine HCl, 1 gamma/kg., I. V. Nicotine (Ease) 25 gamma/kg., I. V. 
Mean Iviean Diff. Mean Mean Diff. 
Response,* ± Standard Response,* ±Standard 
No. mm Hg Error, Pt mm Hg Error Pt 
Drug Dogs Control Test mm Hg Value Control Test mm Hg Value 
+ 6 42.4 SY-2, + -27.3# 69~7 ± 11.5 <0.05 35.7# +5.4# 30.3 ± 11.9 <0.05 
20 mgmfkgm, I. V. 
SY-21 i 6 41.2 ..J+4. &IF 86.0 ± 11.4 <0.05 43.0# -12.0# 55.0 ± 9. 7 <0.05 
1 mgm/kgm. I.V. 
SY ... 21 5 +57.0 -35.6# 92.6 ± 18.5 <0.05 36.S# -13.0# 49.8 ± 12.9 <0.05 
1 mgm/kgm. I.V. 
Unilaterally 
Vagotomized 
(Rt. Vagus) 
*Mean control responses are the average of two in each of the designated numb er of animals. Mean test 
responses are likewise an· average of 2, taken at 10 and 35 minutes after treatment in each of the 
designated number of animals. 
tStatistically significant when less than 0.05 
tN-Ethyl-N-(2-chloroethyl)-benzhydrylamine. HCl 
~N-Ethyl-N-(2-chloroethyl)-9-Fluorenamine. HCl 
fOccasionally these responses were biphasic; only the pressor component was considered in the 
statistical evaluation. 
o-
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Table IX (continued). 
Carotid Occlusion, 1 Minute Nitrogen Inhalation, 1 • .5-2 Minutes 
Mean I-Iean Diff . Mean Mean Diff. 
Response,* ± Standard Response* ± Standard 
No. mm Hg Error, Pt mm Hg Error, Pt 
Drug Dogs Control Test mm Hg Value Control Test mm Hg Value 
+ 
SY ... 2, + 6 3.5.2 +18.? 16 • .5 ± 4.6 <0.0.5 33.0 +9.?# 23.3 ± 3.1 <0.0.5 
20 mf!Jil/kgm, I. V. 
SY-21 i 6 .52 • .5 +21.0 31 • .5 ± ?.8 <0.0.5 3?.3 -2.5 • .5 62.8 ± .5.9 <0.0.5 
1 mgm/kgm. I. V. 
SY-21 .5 . .58.2 +32.2 26.0 ± 6.9 <0.0.5 +22.0 -4.5. 0 6?.0 ± 1?.1 <0.0.5 
1 mf!}Il / kf!Jil. I.V. 
Unilaterally 
Vagotomized 
(Rt. Vagus) 
*Mean control responses are the average of two in each of the designated number of animals. Mean test 
responses are likewise an average of 2, taken at 10 and 3.5 minutes after treat ment in each of the 
designated number of animals. 
tstatistically significant when less than 0.0.5 
+N-Ethyl-N-(2-chloroethyl)-benzhydrylamine. HCl 
§N-Ethyl-N-(2-chloroethyl)-9-Fluorenamine. HCl 
#Occasionally these responses were biphasic; only the pressor component was considered in the 
statistical eva luation. 
SY-21 and SY-2, in the respective doses employed, compare favorably 
with N-(2-bromoethyl)-N-ethyl-l-naphthalenemethylamine.BBr (SY-28) 
( 1.0 mgm..jkgmj and N-( 2-biphenylylo.x:y )-ethyl-N-( 2-chloroeteyl)-butylamine. 
HCl (SY-JO) (5 mgm.jkgm.) with respect to reducing the pressor response to 
carotid occlusion, which were tested under similar conditions previously 
(59); all drugs concerned reduce this response 4o-70 per cent of the con-
trol values. 
c. Effect on mean arterial blood pressure: Neither SY-2 or SY-21 in 
the respective dose employed consistently reduced mean arterial blood 
pressure of the dog. An inspection of Table X reveals that in none of 
the six dogs in which SY-2 was administered did a significant fall in 
blood pressure occur. In one of the ll dogs treated with SY-21, the blood 
pressure fell 10 per cent of the initial level during the first 10 minutes 
after administration but had completely recovered after JO minutes. In 
another dog, the blood pressure decreased about 40 per cent of the initial 
level and had not recovered within 70 minutes after administration of the 
drugs. In all other experiments no appreciable effect on mean arterial 
blood pressure was recorded. Inasmuch as SY-21 and SY-2 had no appreciable 
effect on mean arterial pressure, the recommendations of Maison, ll al. , 
regarding quantitative treatment of carotid occlusion pressor responses 
were ignored (J5). 
It has been previously demonstrated (58) that SY-28 (1 mgm./kgm.) and 
SY-JO (5 mgm..jkgm.) cause an appreciable and prolonged decrease ( 20-JO per 
cent) in mean arterial blood pressure of the anesthetized dog. These com-
pounds were intravenously administered over a 2-minute period, whereas in 
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TABLE X: Effect of N- et b;y-1-11T-(2-ch1oroethy1)-9- f 1uorenamine . HC1 (SY-21) and N-ethy1-N-(2-ch1or oethyl)-
benzhydr-y-lamine. HCl (S'I-2) on mean arteria l blood pressm~e of the anesthetized dog . 
-
-
----- --- ---- -- ------ - -
Mean Femoral Arterial Blood Pressure l1Ell~ Hg 
Drug Exp . 
No. 
.c'..nd of 5 Time in Minutes after End of Injection freinj. -
min.inj. 2 4 6 8 10 30-35 60-70 
-
N-Ethy1-N-(2-ch1oro- 1 120 118 ~32 130 130 132 - 136 145 
eth;)r1) -9-f1uoren- 2 122 112 110 118 126 128 130 12L1 128 
amine . HC1 (Sf -21) 3 100 90 90 88 90 92 - 102 106 
1 mgm./kgrn . 4 130 134 ~32 130 132 128 132 122 120 
(Intact Dogs) 5 126 124 124 118 110 108 90 70 74 
6 150 148 .~..so 150 150 1M ll ~B 150 158 
_..__ 
·- - ---- -·· 
l:iEANS 126 121 123 122 123 i23 125 117 122 
-
N-Bt hy1-N-(2-ch1oro- 1 158 148 148 lL~6 1L~6 148 154 152 158 
ethy1) - 9-fluoren- 2 162 144 .~.32 132 126 128 138 142 144 
amine . HCl (sY-21) 3 164 164 162 - - - 164 17L~ 180 
1 mgm./kgm. 4 166 158 16 2 16 2 162 164 160 166 160 
(Ri ght Vagotomy) 5 136 132 130 130 130 132 130 136 144 
. . 
BEANS 157 149 .~..1.~7 143 lL~1 143 149 154 157 
-
TABlE X (continued) 
.. 
}ffean Femoral Arterial Blood Pressure l:ill Hg 
Drug Exp . 
No. End of 5 Time in Minutes after End of Injection Preinj. min.inj. 2 4 6 8 10 30-35 6o-70 
. . 
N-Ethyl-N-(2-chloro- l 110 107 107 112 112 l~ 116 106 116 
ethyl)-benzhydry1- 2 112 116 132 130 128 128 122 116 120 
amine . HC1 (SY-2) 3 130 1h0 150 150 150 150 144 ll.ro 140 
20 mgm./kgm. 4 152 158 158 156 156 15L~ 150 142 140 
(Intact Dogs) 5 121 120 120 126 128 130 130 128 128 
6 130 134 134 132 128 126 124 116 120 
l!iEAHS 127 129 134 134 134 131+ 131 12.5 127 
the present experiments SY-21 and SY-2 were given over a 5-minute interval. 
While the differences in results may be due to differences in 
potency and dosages used, all the compounds diminished the carotid pressor 
reflex to about the same magnitude, and it is felt that the lack of hypo-
tension following SY-2 and SY-21 was due to a slower rate of administration. 
This is substantiated by previous results in which it was shown that SY-2 
given intravenously in dosages of 10-20 mgm./kgm. over 2-minute intervals 
in the anesthetized dog causes considerable hypotension not fully re-
covered after 120 minutes (33). 
The compounds tested must surely reduce to an appreciable extent 
the tonic sympathetic impulses to the peripheral blood vessels involved 
in maintenance of blood pressure. While no explanation is forthcoming 
concerning maintenance of normal blood pressure follO\'Iing partial adren-
ergic blockade in the experiments reported, it is possible that compensa-
tory reflex increase in cardiac output is involved. Furthermore, a 
direct vasoconstrictive action of the compounds tested has not been 
excluded. 
Discussion: The results show that SY-21 and SY-2 are active adrenergic 
blocking drugs by virtue of their ability to reverse epinephrine, block 
and/or reverse adrenergic reflex pressor responses, as well as those that 
follow injection of nicotine. These drugs are similar to other ethyl-
amines, the dioxanes, Priscoline and ergot and its derivatives in this 
respect (cf. 39, 58 for ref.). 
A blockade of the sympatho-adrenal nervous system by SY-21 and SY-2 
apparently occurs peripherally at the effector cells, which is considered 
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to be true with all known adrenergic blocking drugs except ergot (J9). 
The blockade of the anoxic, carotid sinus, and nicotine pressor responses 
could be located at a central and/or ganglionic site, but a peripheral 
site is more likely for the vasomotor and respiratory responses to epine-
phrine were reversed, while the respiratory changes in nicotine and 
anoxia appeared unaltered. A ganglionic site of action could account for 
all results except the reversal of epinephrine and anoxic pressor responses. 
Nonetheless, a ganglionic site does not seem to be predominantly involved 
for there was no decrease in mean arterial pressure that occurs characteris-
tically with slow intravenous administration of ganglionic blocking drugs. 
Thus a peripheral site of action is the only proposed site of action that 
adequately explains all the data. Furthermore, the conclusive studies 
by Nickerson with Dibenamine regarding its peripheral site of action, 
suggest strongly that SY-21 and SY-2 act at the same site since they are 
closely related chemically and pharmacologically (46). 
The slow intravenous administration of effective doses in anesthetized 
dogs of SY-21 and SY-2 did not produce any effects that could not be refer-
able to peripheral blockade of adrenergic nerves. A lack of significant 
cholinergic properties was reported previously for both drugs (see above, 
and JJ), and no cholinergic effects (e.g., drop in blood pressure in un-
atropinized dogs and a change in heart rate) were not observed in these 
experiments. Both drugs have been shown previously to lack appreciable 
antihistaminic or anti-acetylcholine properties (see above, and 33), and 
the administration of SY-21 in oral doses of 5 mgm./kgm. twice daily to 
dogs produced no observable side effects except a decrease in appetite 
66 
probably due to localirritating properties (lJ). Hence, the results 
of these experiments support previous conclusions (see above, and JJ) 
that these drugs are among the most specific and effective halogenated 
ethylamine adrenergic blocking drugs reported. 
Summary: N-Ethyl-N-(2-chloroethyl)-9-fluorenamine.HCl (SY-21) and 
N-ethyl-N-(2-chloroethyl)-benzhydrylamine.HCl (SY-2) in doses of 
1.0 and 20 mgm.fkgm., intravenously, respectively, have been shown to be 
active adrenergic blocking drugs by virtue of their ability to reduce, 
block or reverse the pressor action of epinephrine, nicotine, carotid 
occlusion, B~d anoxia in dogs. The data obtained support previous con-
clusions regarding the agents high order of specificity and a per'ipheral 
adrenergic blocking actio~. 
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Aryl and/or alkyl substitution of one or two of the B-chloroethyl 
groups of bis or tris-:B-chloroethylamine (nitrogen mustards) was shown 
in 1946 to reduee markedly the toxicity of these substances and to confer 
new and interesting pharmacologic properties upon the 2-haloalkylamine 
grouping. These compounds, of which N, N, dibenzyl-B-chloroethylami.ne 
(Dibenamine) was the forerunner (l), possess the ability to block and 
reverse many of the pharmacologic effecte of epinephrine, as well as 
reduce or abolish the effects mediated over the sympatho-adrenal nervous 
system. 
Evidence accumulated indicating that Dibenamine was the most specific, 
lUbei t not the .1110st potent, adrenergic blocking drug, as compared to 
notoriously non-specific and toxic members existing in the same class 
(ergot deriTatives, yohimbine, dioxanes, and so forth. (See (2) for 
reference and disanssion). 
In 1947 it was shown by Loew (3) 1 and, subsequently by Kerwin, 
.tl_ &. (4), Hunt (5) 1 Henderson, .tl, ~ (6), and Nickerson (?), that 
the dibenzyl radical was not the only aryl substituent which conferred 
low toxicity and adrenergic blocking properties to the B-chloroethyl group 
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in nitrogen mustards. Hence, alp~naphthylmethyl, biphenylyloxy, phenylethyl, 
phenoxy, benzhyd.ryl, B.nd 9-fluorenyl su.bstituted derivatives were found to 
be active adrenergic blocking drugs, some homologu.es of which were far 
more potent than Dibenamine in this respect. However, certain of these 
derivatives were found not to be as specific as Dibenamine. Hence, co~ 
pounds possessing appreciable antihistaminic properties (alpha-napht~l-­
methyl1 and biphenylyloxy deriTatives) were described (8); and others 
proved to be cholinergic (e.g., N, N-d.imethyl-2-ohloro-2-:phenylethylamine, 
(9). 
From the available evidence it appeared that aryl and/ or al.kyl sub-
stitution of one or two of the B-chloroethyl groups of the nitrogen mustards 
altered the toxicity but did not reduce the potential chemical reactive-
ness inherent in the ~-chloroethyl radical (see (10) for disaussion of 
chemical reactivity of nitrogen and sulfur mustards). It was apparent, 
however, that the nature of the aryl substituent modified this reaetiYe-
ness of this group so that it bece~e more or less specific. This in turn 
was reflected in predominant pharmacologic effects of a given deriyatiYe 1 
in contrast to the rather wide-spread and maJrl.fold pharmacologic effects 
of the nitrogen mnstards (10). Nonetheless, other pharmacologic effects 
which appear in a given compound are in addition to prominent adrenergic 
blocking properties; thus most aryl derivatives of B-chloroethylamine 
which have been described are classified in this category. 
In view of the possible uses of adrenergic blocking drugs in 
medicine, and the fundamental usefu.l.n.ess of these drugs in delimiting 
functions of the sympathetic nervous system. the importance of knowing 
the specificity and potency of drugs is evident. Aryl derivatives possess 
desirable properties in that they are long-acting and highly poten'\i and 
effective. Unfortunately, as pointed out above, not all derivatives 
appeared as specific a.s desired1 and, in ad.di tion, specificity among 
these agents had not yet been placed in quantitative terms. 
With these points in mind, studies of the specificity of action of 
some of the more potent and better known aryl-haloalkylamines were made 
on the isolated seminal vesicle of the guinea pig by the Magnus techni~ue. 
Specificity of drug action was inferred from the relatiTe concentrations 
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of each adrenergic blocking drug required to inhibit the spasmogenic 
effects of equi-effective doses of epinephrine, nor~epinephrine, histamine, 
BAd acetylcholine, as compared to control contractions made in the absence 
of the antagonist. 
The measurement data obtained were converted to all-or-none data by 
designating that a given trial with an antagonistic drug was a positive 
trial if the per cent reduction was 50 per cent or greater; any value below 
this was a negative trial. Thus, small doses of antagonist yielded 
relatiTely few positive trials, and increasingly larger doses resnlted 
in greater proportions of positive trials. 
The data. were analyzed statistically by the graphic analysis of 
ldtchfield and Wilcoxon (ll) to forecast the relative concentration 
(in mcg./100 cc.) producing 50 per cent or greater inhibition of the 
spasm induced by the active drug in 50 per cent of the trials (ED5o) 
and the 95 per cent confidence limits of these estimates. 
Comparisons of the EDjO values obtained with the adrenergic block.... 
ing drugs antagonizing epinephrine revealed that N-ethyl-N-(2-chloroethyl) 
-9-fluorenam.ine.HCl (sY ... 2l, EDsoEpi • 0.52) was the most effective antagonist 
of epinephrine. This was followed in order by: N-ethyl-N-(2-chloroethyl)-
benzhyd.rylamine.HCl (SY-2, EDsoEpi • o. 75); N-ethyl-N-(2-bromoethyl)-
:naphthalenemethylam.ine. BBr (SY-28, ED50Epi • 1.37); N, N-(2-chloroethyl)-
dibenzylamine.HCl (Dibenamine, EDsoEpi = 2.60) and, 2-(2-biphenylyloxy)-
2'-chlorotriethylamine.HCl (SY-S, EDsoEpi • 3.03). As to be expected, 
atropine sulfate (EDsoEpi .. 1330) and pyranisamine (EDsoEpi • ca.. 12-
24,000) were highly ineffective in antagonizing epinephrine under the 
condi tiona employed. 
Comparison of ED.5o Norepi values yielded the same order of potency. 
The individual values were uniformly less than the corresponding ED.50:E.pi• 
The EDsoNorepi to EDSOEpi ratio was o.a in each case examined and indicates 
that less drug was required to inhibit nor-epinephrine than an equi-
effective amount of epinephrine, although the difference was statisticaJ.ly 
significa.nt in only 2 of the 4 comparisons made. This result suggests. 
that the greater msceptibili ty to blockade by these drugs of epinephrine 
pressor effects, as compared to nor-epinephrine. is due to significantly 
greater vasodilati:ng_, properties of the former, and not to differences 
in the amines, per se, or site of action of the pressor agents. 
Antihistaminic properties, as judged by the ability to reduce hista-
mine spasm, were revealed in all of the aryl-haloalkylamines exrunined. 
The most potent aryl-haloalkylamine in this respect (SY-28, EDSOHist 
• 0.71), however, was far less effective than pyranisamine (Neo-antergan 
maleate, ED.5oHist • .053) tested under the same conditions. The anti-
histaminic activity of the aryl-haloa.J.kylamines {as was the anti-epinephrine 
activity) was irreversible (and hence, probably non-competitive) under 
these conditions since the drugs, once added to the muscle bath, could 
not be washed from the tissue. 
The ratio, ED.50Hist/ ED50Epi• each from the same antagonist gives 
some measure of the relative specificity. This ratio, calculated for 
each antagonist, varied from 44 (SY-2) to 0.5 (SY-28). Hence, the same 
relatio~hip that existed between epinephrine and nor-epinephrine 
(EDSONorepi to EDSOEpi ratio for each antagonist • 0.8) does not exist 
between histamine and epinephrine and does not Stlpport the concept that 
epinephrine and histamine act in similar manners or on the same receptors. 
Compe"rison of the ratio, EDsoHist to EDsoEpi• reveal.ed that SY~ 
(Ratio = 44) was the most discriminating under these conditions, followed 
by SY-21 (20), Dibenamine (lJ), SY-8 (2) and SY-28 (o.s). The ratio of 
0.5 obtained with SY-28 indicates that this drug is more effective in 
anta&enizing histamine than epinephrine, and as such, should be classified 
as an antihistaminic. 
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While the properties of these aryl-haloalkylamines were qualitatively 
similar with respect to histamine, epinephrine, and nor-epinephrine antag-
onism, marked differences were apparent with respect to antagonism of acetyl-
choline. Thus, SY-2 and Dibenamine, were. found to be incapable of blocking 
acetylcholine-induced spasm in quanti ties that did not produce spasm 
themselves (?00 to 1400 times the respective ED50Epi) • SY-21 potentiated 
acetylcholine spasm markedly in doses of soo-1000 mcg./100 cc., quantities 
in themselves slightly spasmogenic. SY-28 and SY-8 were found to block 
acetylcholine. The concentrations required to do so were much above those 
of atropine sulfate but only 8 (SY-8) and 68 (SY-28) times their respec-
tive EDSOEpi. The blocking properties of SY-28 and SY-8 were partially 
reTereible by washing and differ in this respect from anti-epinephrine and 
anti-histamine activity. The modifying importance of the aryl radical is 
brought out by these results since the drugs studied differed only in the 
nature of the aryl radical (all were aryl-ethyl-B-chloroethylamines 
except Dibenamine--an aryl-benzyl-B-chloroethylamine). 
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The results of these experiments revealed that aryl-haloalkylamine 
adrenergic blocking drugs possess pharmacologic properties other than 
anti-epinephrine activity, which may approach or overshadow the adrenergic 
blocking activity. The great pharmacologic potentialities of the B-
chloroethylamine groU,p appears to have been rendered more specific by 
juxtaposition of a suitable aryl radical, although the specificity exhibited 
does not approach certain other antagonists of different classes (e.g., 
atropine vs. acetylcholine~ and pyran.isamine va. histamine). 
Finally, two of the most specific drugs, as determined above, were 
selected and studied in intact animals in order to assess, in some 
measure, their range of activity and site of action. The method employed 
was one in which the blocking activity of the d.r'ut;s against epinephrine 
and adrenergic reflex pressor responses were obtained in the anesthetized dog 
by 1) carotid occlusion and 2) anoxia {nitrogen inhalation). In addition, 
anrenergic effects, manifested as a rise in blood pressure, was induced 
by injections of nicotine (25 mog./kgm~, i;v.) acting primarily at the 
ganglionic level, and epinephrine {1 meg. /kgta. ., i.v.) acting at the 
effector cell level. 
Both SY.-2 (20 mgm. /kgm., i.v.) and SY-21 (1. 0 mgm. /kf!.m., i.v.) re-
duced, blocked or reversed the adrenergic responses due to carotid 
occlusion (reduced), anoxia (reversed), nicotine (reversed), and epinephrine 
(reversed). The data obtained suggested that SY.-21 was more potent than 
SY...2 1 even more so than the differential in doses indicate. 
The data are interpreted as to suggest that a peripheral site of 
action is responsible for blockade of all the responses. In addition, no 
effects were observed, under the conditions employed, that could not be 
explained as due to peripheral blockade of the sympatho-adrenal nervous 
system. 
The experiments support the previous conclusion that SY-2 and SY-21 
are among the most specific aryl-haloal~lamine adrenergic blocking drugs 
available. 
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